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Abstract?
 
Müllerian aplasia (MA) is a congenital female reproductive disorder featured by loss of a 
functional uterus and vagina in otherwise healthy females. The prevalence world-wide is 
estimated to be at least 1:5000 female births. Only a few MA patients have been described 
with mutations or copy number variations (CNVs) and therefore the cause of the disorder is 
unknown for the majority of patients. 
 
The aim of this study was to learn more about the genetics of MA. This was accomplished by 
studying candidate genes, CNVs and methylation defects, as well as by searching for new 
genes that could be involved in the development of the disorder. As a platform for the 
study,  a  large  sample  set  of  Finnish  MA  patients  with  well-characterized  clinical  data  was  
used. 
 
Initially the involvement of the male Y chromosome was studied in MA patients, because of 
the MA phenotype. During male sexual development, the Müllerian ducts (MDs) regress as a 
result of anti-Müllerian hormone (AMH) secreted by the developing testes, which in turn 
develops under the regulation of Y chromosomal genes, most importantly the testis-
determining gene SRY. Testis-specific protein 1-Y-linked (TSPY1) was investigated as well as 
a large number of additional Y-chromosomal loci. The results were negative with no 
detectable presence of the studied fragments, indicating that Y chromosomal gene 
regulation is not a cause of the disorder in this patient cohort. 
 
Epigenetic factors changing the expression of genes instead of the structure of the DNA 
itself have been implicated as a cause of MA. Therefore, DNA methylation studies of the 
imprinting control region (ICR1) of H19, (H19, imprinted maternally expressed transcript 
(non-coding)) and the gene itself were performed in order to evaluate its role in the 
development of MA. Aberrant methylation levels of H19 ICR1 were not detected in MA 
patients, however aberrant methylation within H19 was observed. 
 
CNVs  of  the  short  stature  homeobox  gene  (SHOX)  were  evaluated  in  the  Finnish  cohort,  
because of a finding suggesting SHOX duplications as  MA causative.  However,  none of  the 
Finnish patients showed presence of SHOX CNVs, possibly indicating population differences 
in the underlying cause of MA. 
 
Finally,  a  genome-wide  search  for  novel  CNVs  revealed  nine  rare  CNVs  in  eight  out  of  50  
(16%) studied patients. Of these nine CNVs, two had been previously reported in association 
with  MA,  namely  deletions  in  16p11.2  and  17q12.  Further  CNV  screening  in  an  enlarged  
patient sample set revealed four more 16p11.2 deletions, resulting in a total of 5/112 (4.5%) 
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MA patients with deletions in the region. The 16p11.2 region includes one gene with known 
function in embryonic development, the T-box gene TBX6, which therefore was chosen for 
further screening by Sanger sequencing. By this method, a novel splice site mutation 5´of 
exon 5 was found in two patients. In addition, two rare polymorphisms were significantly 
more common in patients than in controls, suggestive for a role in MA. LIM homeobox 1 
(LHX1), located within the 17q12 deletion region and recently reported as causative for MA 
in two patients, was also sequenced and three novel variants in five MA patients were 
identified, thereby strengthening its importance in the development of MA. 
 
The major result of this study was the finding of a new gene, TBX6, linked to MA. 
Additionally, novel LHX1 variants  were  found  in  MA  patients,  as  well  as  rare  CNVs.   
Furthermore, 4/112 (3.6%) patients were shown to carry both a TBX6 or LHX1 variant and a 
CNV, highlighting the complex and multifactorial background of MA.  
 
So far, the genetics of MA has proved challenging to decipher. Here we were able to add a 
new gene, TBX6, to the few previously associated with MA and confirm the previously 
identified CNVs in 16p11.2 and 17q12 and LHX1 mutations, in a small number of patients. 
This study strengthens the hypothesis of the complex inheritance of the condition. It also 
highlights the importance of validating new results in independent patient series as well as 
the importance of reporting both positive and negative results to the scientific community. 
The results of this study are inspiring for future research and will pave the way for new gene 
and mutation discoveries underlying MA. 
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1. Introduction?
 
Throughout life, fertility and the ability to reproduce have been keystones for survival. In 
modern times, reproduction of each individual is not a prerequisite for the human 
population to survive, however, infertility and problems related to reproduction have 
become a growing concern in society. 
 
Globally, infertility due to male and female factors affects one in every four couples in 
developing countries (World Health Organization, WHO). Female infertility can manifest as 
an inability to become pregnant, maintain a pregnancy or carry a pregnancy to a live birth. 
Müllerian anomalies are congenital disorders including malformations of the female 
reproductive duct (uterus, oviducts and vagina) associated with a wide range of fertility 
problems, ranging from increased risk of miscarriage to absolute infertility. Müllerian 
anomalies are identified in approximately 2-3% of females and the number might be even 
higher because these anomalies are frequently undiagnosed. Genetic factors have been 
suggested to contribute to the development of Müllerian anomalies (Hammoud et al. 2008). 
 
Müllerian aplasia (MA) is a congenital disorder of the female reproductive duct 
characterized by lack of functional uterus and vagina in otherwise healthy females. It has an 
immense impact on a woman´s life due to infertility and inability to have a normal sex life 
without  treatment.  Psychosocial  problems  are  also  commonly  associated  with  MA.  The  
frequency of MA is estimated to be at least 1 in 5000 female births.  
 
This study was conducted in order to gain further knowledge about the genetics behind MA 
and how it affects the normal development of the female reproductive organ. Although that 
may not help the treatment of this disorder, it would be of great importance to affected 
females to understand how MA develops and why they have been born with this 
abnormality. 
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2. Review?of?the?literature?
 
The development of a human being starts from fertilization and continues into adulthood. 
This literature review focuses on the development of the female reproductive duct (FRD) 
that takes place in the early embryo, and the disturbances in relation to that development. 
 
2.1?Development?of?the?female?reproductive?duct?
 
The female urogenital system develops from the intermediate mesoderm (IM) of the 
embryo and includes the kidneys, ovaries, the urinary system and the FRD, which is 
composed of the oviducts (Fallopian tubes), uterus, cervix and vagina. The FRD derives from 
the Müllerian or paramesonephric ducts (MDs), which are dual ducts formed as 
invaginations of the coelomic epithelium (CE) of the developing urogenital ridge. The 
invagination  of  the  MDs  starts  around  embryonic  day  11.5  (E11.5)  in  mice  (Cunha  1975,  
Kobayashi et al. 2003). The formation of the MDs can be considered as a three-step event 
(Figure 1). In the first phase, cells in the CE are fated to become MD specific. This is evident 
as a thickening of CE cells and LIM homeobox protein 1 (Lim1, also called Lhx1) and paired 
box gene 2 (Pax2) expression at the site of MD initiation (Figure 1a) (Kobayashi et al. 2004, 
Orvis et  al. 2007). In the second phase (Figure 1b), expression of wingless-related MMTV 
integration  site  4  (Wnt4)  from  the  mesonephros  (primitive  kidney)  or  the  CE  initiates  the  
invagination of the specified CE cells and the MDs elongate caudally until they reach the 
Wolffian ducts (WDs) (Vainio et al. 1999, Orvis et  al. 2007).  The  WDs  (also  called  
mesonephric ducts, because they connect the mesonephros to the cloaca) are the 
primordial anlage for the male reproductive system developing into the epididymis, vas 
deferens and seminal vesicle (Roberts et al. 2002). 
 
The third and last phase of MD formation includes the elongation of the MDs (Figure 1c). 
This happens in close contact with the elongation of the WDs, and until recently it was 
thought that WD cells contribute to the formation of the MDs (Gruenwald 1941, Vainio et 
al. 1999, Kobayashi et al. 2005, Orvis et al. 2007). Experimental work performed on chicken 
and mouse embryos have more recently ruled out the necessity of WD derived cells for 
successful MD formation (Guioli et al. 2007, Orvis et  al. 2007). However, expression of 
wingless-related MMTV integration site 9b (Wnt9b)  in  the  WD  cells  seems  to  affect  MD  
formation in a paracrine manner (Carroll et al. 2005). The elongation of the MDs proceeds 
posteriorly towards the urogenital sinus, which is derived from the endodermal germ layer. 
In the 8th week of human development (~E12.5  in mice), the MDs join and fuse with each 
other at the midline, giving rise to the characteristic morphological shape of the FRD with a 
lower/caudal/posterior one-luminar tube (upper vagina, cervix and uterus) and the 
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upper/cephalic/ anterior non-fused region (Fallopian tubes and infundibulum). The 
elongation of the MDs is completed by E13.5 in mice (Kobayashi et  al. 2003, Kurita 2011, 
Fritsch et  al. 2012). The lower part of the vagina is derived from the urogenital sinus with 
endodermal origin (Cunha 1975). Interactions between the urogenital sinus, MDs and WDs 
have been shown to be important for vaginal development (Fritsch et al. 2012). 
 
 
 
 
Figure 1: A schematic view of the development of the female reproductive duct (FRD). In the first 
phase (a) coelomic epithelium (CE) cells expressing Lim1 and Pax2 become specified for Müllerian 
duct (MD) formation (shown in orange). In the second phase (b) invagination occurs due to Wnt4 
expression and in the third phase (c) elongation of the MDs toward the urogenital sinus proceeds. 
Pax2 is involved in the MD maintenance and elongation. Wnt9b is secreted from the Wolffian ducts 
(WDs) to promote MD elongation. Genes expressed in the WDs are shown in blue and in both WDs 
and  MDs  in  red.   Reprinted  from  Trends  in  Endocrinology  &  Metabolism,  Volume  20,  Ma  L,  
Endocrine disruptors in female reproductive tract development and carcinogenesis, 357-363, 
Copyright (2009), with permission from Elsevier. 
 
The MDs and the WDs are primordial ducts existing side by side in the developing embryo. It 
is  not  until  the  stage  of  sex  differentiation  that  one  of  duct  systems  develops  further,  
whereas the other one regresses. 
 
2.1.1?Genetics?of?sex?determination?
 
Initially the embryo has bipotential gonads and possesses the possibility of developing into 
either sex.  In humans, the sex is determined genetically with XX individuals becoming 
females  and  XY  individuals  becoming  males.  If  the  embryo  expresses  the  Y-chromosomal  
testis-determining gene SRY the gonads differentiate into testes and start secreting 
testosterone, AMH (also called Müllerian inhibiting substance, MIS, or Müllerian inhibiting 
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factor, MIF) and insulin-growth factor (InsI3) (Nef et  al. 2000). Testosterone promotes WD 
differentiation into the organs of the male reproductive system (epididymes, vas deferentia 
and seminal vesicles). AMH is a transforming growth factor-? (TGF-?) superfamily member 
secreted by the Sertoli cells in the testes (Josso et  al. 1993).  AMH  eliminates  the  MDs  
(Behringer et al. 1994) resulting in absence of MD derivatives in the embryo, which in mice 
is completed at embryonic day 16.5 (Kobayashi et  al. 2004).  InsI3  is,  together  with  
testosterone and AMH, involved in the descent of the testis (Nef et al. 2000). During normal 
female development, with absence of the Y chromosomally located SRY, the male gonadal 
hormones are not produced and the anlage for the male reproductive system, the WDs, 
regress. The ovaries produce estrogen that enables the development of the MDs into 
uterus, Fallopian tubes, cervix and upper two thirds of the vagina (Figure 2) (reviewed in 
Kobayashi et al. 2003, Matzuk et al. 2008).  The  origin  of  the  lower  part  of  the  vagina  has  
been an issue of debate, but the general understanding is that it is a derivative of the 
urogenital sinus (reviewed in Kurita, 2011). 
 
 
 
Figure 2: Development of the normal female and male reproductive ducts during sexual 
differentiation. AMH  =  Anti-Müllerian  Hormone;  T  =  Testosterone.  Reprinted  by  permission  from  
Macmillan Publisher Ltd: [Nature Medicine](Matzuk MM and Lamb DJ. The biology of infertility: 
research advances and clinical challenges. Nat.Med. 14:1197-1213), copyright (2008). 
 
In puberty the adolescent takes a big leap into young adulthood, which involves many 
physical and psychosocial changes. In girls, the initial sign of puberty is normally breast and 
pubic hair development, followed by a growth spurt and menarche (onset of menses). The 
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normal age of pubertal onset is 8 years (Marshall et al. 1969, Nebesio et al. 2007) and 
puberty lasts on average about 3 years. However, individual differences vary greatly and the 
normal range is wide.  Ethnicity along with genetic and environmental factors is known to 
impact pubertal timing (Euling et  al. 2008).  The  Tanner  stages  describing  five  stages  of  
breast and pubic hair development is widely used for assessing the various steps of sexual 
development during adolescence (Tanner 1962, Marshall et  al. 1969).   Female  puberty  is  
driven by a normally functioning hypothalamic-pituitary-ovarian axis with associated 
hormones, such as gonadotrophin releasing hormone (GnRH), follicle-stimulating hormone 
(FSH) and luteinizing hormone (LH), stimulating i.e. estrogen production, and follicular and 
endometrial growth (Nebesio et al. 2007, Bordini et al. 2011). 
 
2.1.2?Genes?and?pathways?in?the?development?of?the?female?reproductive?duct??
 
Although the development of the FRD is fairly well-known, the regulation of the genes 
involved in FRD development is still far from fully established. Most of the genes known to 
be involved in FRD regulation have emerged from mouse studies, where specifically mutant 
mouse strains with urogenital phenotypes have been informative. Genes required for 
successful development of the mouse FRD are briefly introduced in the following sections 
and their expression in the mouse reproductive duct is summarized in Table 1.  
 
Lim1 encodes a transcription factor (TF) essential for head and kidney development 
(Shawlot et al. 1995). Lim1 is also expressed in the IM differentiating into the WDs and the 
MDs (Barnes et al. 1994, Tsang et al. 2000). The female Lim1 knockout mouse lacks a uterus 
and oviducts, but possesses ovaries (Kobayashi et  al. 2004). Pax2,  also  encoding  a  TF,  is  
important for multiple steps of urogenital development. The Pax2 homozygous (-/-) mutant 
mouse has absent kidneys and ureters. The WD and MD derivatives form initially but soon 
regress, resulting in complete lack of genital tract in both sexes (Torres et al. 1995). Empty 
spiracles  homeobox  2  (Emx2) mutant mice die soon after birth due to urogenital failure. 
Apparently, the initiated WDs degenerate and the MDs never start to form (Miyamoto et al. 
1997). Wnt4 is crucial for MD initiation, male sexual differentiation and female germ line 
maintenance.  This  was  shown  with  a  Wnt4 knockout mouse where females are strikingly 
masculinized with absence of MDs and presence of WDs. The mutant also had activated 
testosterone production and diminished oocyte production (Vainio et  al. 1999). Notable is 
that  all  four  genes  (Lim1, Pax2, Emx2 and Wnt4)  are  involved  both  in  MD  formation  and  
kidney development, suggesting shared underlying mechanisms in both pathways (Stark et 
al. 1994, Shawlot et al. 1995, Torres et al. 1995, Miyamoto et al. 1997, Tsang et al. 2000). 
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Two other genes from the Wnt family gene pathway, Wnt7a and Wnt9b, homologues to 
Drosophila segment polarity genes, are crucial in MD formation. Mutant mouse studies have 
shown Wnt7a to be important for MD regression in normal male development. The female 
mutant mouse showed impaired development of the MDs, resulting in infertility due to 
absent oviducts and a less muscular and slender uterus. The male mutant showed 
persistence of the MDs (Parr et al. 1998). Wnt9b is  expressed  in  both  sexes  in  the  WD  
epithelium during mouse E9.5-E14.5 and necessary for MD elongation. The mutant mouse 
model showed multiple urogenital defects, including lack of uterus and upper vagina in 
females (Carroll et al. 2005). 
 
Hepatic nuclear factor 1? (Hnf1?, also called Tcf2), is a major player in epithelial cell 
development during organogenesis in several organs with tubular structures. Expression of 
Hnf1? is especially evident from an early phase in the development of the urogenital 
structures in mouse (Coffinier et al. 1999, Reber et al. 2001). In humans, HNF1? has been 
associated with maturity-onset diabetes of the young (MODY), with diabetes mellitus, renal 
cysts and other renal malformations (Kolatsi-Joannou et al. 2001, Bingham et  al. 2002). 
Interestingly, also malformations of the FRD, such as bicornuate uterus, uterus didelphys 
(Bingham et al. 2002) and MA (Lindner et al. 1999) have been found in some of the patients 
with HNF1? mutations. HNF1? is also a risk gene for several forms of cancer, including 
endometrial and ovarian cancer (Kato et al. 2009). Dach1 and Dach2, both members of the 
Dachshund gene family of conserved transcriptional cofactors, have been shown as 
important players in MD development. Interestingly, the single Dach1 or Dach2 knockout 
mouse does not exhibit a FRD phenotype, but the combined mutant (Dach1/Dach2) has a 
severely disrupted FRD development. Also Lim1 and Wnt7a expression is abnormal in these 
double knockouts (Davis et al. 2008). 
 
In mouse mutants with deficient Wnt5a expression,  the  posterior  part  of  the  FRD  (cervix  
and vagina) fails to form. The anterior parts of the FRD (Fallopian tubes and uterine horns) 
are present, however the uterine horns have a reduction in length and luminal changes 
compared to wild-type (Miller et  al. 1998, Mericskay et  al. 2004). Retinoic acid nuclear 
receptors (RARs, subtypes ?????), which are transcriptional transducers of the retinoic 
signal, regulate development of several tissues and organs. Compound mutant mouse 
models of RARs have a wide range of developmental defects affecting neck, trunk and 
abdominal regions including defects of the urogenital system. Depending on the genotype 
of the double mutant, the defects vary from mild aplasia of the kidneys and apparently 
normal FRD to renal aplasia and lack of all MD derivatives (Mendelsohn et al. 1994). Renal 
and  urogenital  defects  are  also  found  in  discs  large  homolog  1  (Dlgh1)  mutants,  such  as  
hypoplastic kidneys and ureters, and absent vagina and seminal vesicles (Iizuka-Kogo et al. 
 
 
17 
 
 
2007). ?-catenin knockouts are found with defective oviduct patterning and MD formation 
(Arango et al. 2005, Deutscher et al. 2007). 
 
 
Table 1: Genes involved in mouse reproductive duct development, their expression in the 
Müllerian (MD) and Wolffian (WD) ducts and their female urogenital phenotype. 
 
Gene Expression  Knockout phenotype Reference 
Lim1 MD, WD no uterus, no oviducts, normal 
ovaries 
Kobayashi et al. 2004 
Pax2 MD, WD no kidneys, no ureters, no MD or 
WD derivatives 
Torres et al. 1995 
Emx2 MD, WD no MD, no WD Miyamoto et al. 1997 
Wnt4 MD no MDs but WDs   (masculinized), 
?testosterone, ?oocyte 
production 
Vainio et al. 1999 
Wnt7a MD (F) no oviducts, uterine 
aberrations 
(M) MD persistence 
Parr & McMahon 1998 
Wnt9b WD no upper vagina, no uterus Carroll et al. 2005 
Hnf1?/Tcf2 MD, WD ND Reber et al. 2001 
Dach1 MD no disruption in FRD Davis et al.2008 
Dach2 MD no disruption in FRD Davis et al.2008 
Dach1/ 
Dach2 
MD the double knockout has 
hypoplastic oviducts and uterus, 
vaginal aplasia 
Davis et al.2008 
Wnt5a MD no cervix, no vagina, uterine horn 
malformation 
Miller et al. 1998 
RAR ????? ND wide range from normal to lack of 
all MD derivatives 
Mendelsohn et al. 1994 
Dlgh1 ND hypoplastic kidneys and ureters, 
no vagina 
IIzuka-Kogo et al. 2007 
?-catenin MD oviduct malformation, 
hypotrophic uterine horns 
Deutscher et al.2007 
Wt1 ND no kidneys, no gonads Kreidberg et al. 1993 
Lamc1 MD, WD no uterus, occasionally no 
oviducts 
Willem et al. 2002 
Hoxa10 MD (uterus) no uterotubal junction, upper 
uterus with oviduct appearance 
Benson et al. 1996 
Hoxa11 MD (lower uterine 
segment and cervix) 
reduced stroma and gland 
development in uterus 
Gendron et al. 1997 
Hoxa13 MD (ectocervix and 
upper vagina) 
no caudal portion of MD Warot et al. 1997 
Pbx1 ND no kidneys, no MDs Schnabel et al. 2003b 
ND = no data concerning expression in the reproductive duct or urogenital status 
(F) =female, (M) = male 
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Wilm’s tumour nephroblastoma, the most common intra-abdominal solid tumour in 
children,  is  associated  with  mutations  in  Wilms  tumor  1  (WT1) (Reddy et  al. 1996). Wt1 
mutant mice fail to develop kidneys and gonads, suggesting a role for the gene in urogenital 
development (Kreidberg et al. 1993). Laminin, gamma 1 gene (Lamc1) is a basal membrane 
component important in organ and tissue development. Lamc1 mutant mice were found 
with  blind-ending  WDs  and  MDs  and  the  females  lack  a  uterus  and  occasionally  also  
oviducts (Willem et al. 2002), suggesting that the gene has a role in urogenital development. 
 
Last but not least, defects of the developmental homeobox (Hox) genes Hoxa10, Hoxa11 
and Hoxa13 have been reported as crucial for proper patterning of the FRD (Benson et al. 
1996, Gendron et  al. 1997, Warot et  al. 1997, Zhao et  al. 2001). The pre-B-cell leukemia 
homeobox 1 (Pbx1)  gene  is  a  coactivator  of  Hoxa genes and involved in skeletal 
development and patterning (Selleri et al. 2001), kidney formation (Schnabel et  al. 2003a) 
and MD development (Schnabel et  al. 2003b). Mouse studies have shown that Pbx1 
expression is essential for successful development of the urogenital ridge and of multiple 
organs evolving from that (Schnabel et al. 2003b). 
 
From the aforementioned genes relevant in the development of the FRD three main 
pathways can be distinguished. These are the AMH pathway, the Wnt pathway and  the  
Hoxa pathway (Table 1). All three are crucial for MD formation and all three have been in 
key focus when studying the underlying genetic defects of the FRD. 
 
The AMH pathway is of interest for FRD development due to its key function in males, which 
is regression of the MDs. AMH signaling is mediated through a type 2 receptor (Amhr2, also 
called Misr2) expressed during fetal development in the mesenchyme cells surrounding the 
developing MDs and in the MD (Mishina et al. 1996, Nef et al. 2000, Kobayashi et al. 2011). 
Mutations in AMH or AMHR2 cause  persistent  Müllerian  duct  syndrome  (OMIM  261550)  
with presence of uterus and Fallopian tubes in males, who often have cryptorchidism 
(undescended testes) with otherwise normal male genitalia (Imbeaud et  al. 1994).  Amh-
mutant male mice also have uterus and oviducts, but fully descendent testes (Behringer et 
al. 1994). AMH is probably the only ligand for Amhr2, because both Amh and Amhr2 mutant 
male mice have the same phenotype (Mishina et al. 1996).  The binding of  AMH to Amhr2 
recruits a type 1 receptor mediating the AMH signal in vivo.  Type 1 bone morphogenetic 
protein (BMP) receptor, Bmpr1a (also known as activin receptor-like kinase-3, Alk3), has 
been identified as such an AMH type 1 receptor, because conditional male mutants were 
found with uterus and oviducts (Jamin et al. 2002). The matrix metalloproteinase 2 (Mmp2) 
has been suggested as a downstream component of the AMH pathway involved in the 
apoptotic events causing MD degeneration, but the mutant Mmp2 male mice showed no 
urogenital phenotype and thereby the mechanisms for the epithelial regression remains 
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unknown (Roberts et al. 2002). In women, AMH is mainly expressed by the granulosa cells in 
the ovaries and has been suggested as a marker of ovarian follicle reserve and female 
fertility (Bentzen et al. 2013). 
 
The Wnt genes are a large family of secreted protein growth factors highly conserved 
between vertebrate species and acting in a wide variety of roles during development. Wnt 
signals are transduced through different intracellular pathways, of which the canonical 
“Wnt/?-catenin” pathway primarily regulates cell fate during development (Miller 2002). In 
the presence of a Wnt ligand and its binding to the Frizzled receptor,  ?-catenin is 
accumulated  in  the  cytoplasm  and  imported  to  the  nucleus  where  it  serves  as  a  
transcriptional coactivator of TFs for the T-cell factor (TCF)/lymphocyte enhancer factor 
(LEF) family (reviewed in Rao et al. 2010). 
 
Taken together, at least four Wnt family members (Wnt4, Wnt5a, Wnt7a and Wnt9b) are 
known to be important for successful FRD development (Miller et al. 1998, Parr et al. 1998, 
Vainio et al. 1999, Mericskay et al. 2004, Carroll et al. 2005). Interestingly, members of the 
Wnt gene family seem to be capable of substituting each other. This was shown in the work 
of Carroll et al, where the induction of the mesonephric and metanephric tubules and the 
elongation of the MD in Wnt9b mutants were rescued by Wnt1 expression (Carroll et al. 
2005). A link between the AMH and Wnt/?-catenin pathways was established when ?-
catenin was shown to mediate AMH signaling during MD regression in normal male 
development (Kobayashi et al. 2011).  Thereby,  ?-catenin  was  shown  to  have  dual  roles  in  
reproductive duct development: one for MD differentiation in females (Arango et al. 2005, 
Deutscher et al. 2007) and the other for MD regression in males (Kobayashi et al. 2011).  
 
The Hoxa pathway is especially important in regulating the spatiotemporal interactions 
between TFs and signaling molecules in order to obtain the correct compartmentalization of 
the FRD. Hoxa9 is expressed in the Fallopian tubes, Hoxa10 and Hoxa11 in the uterus, and 
Hoxa13 in the upper vagina (Taylor et al. 1997). 
 
Cooperation between the abovementioned genes and pathways as well as between factors 
acting downstream and upstream of them is fundamental for proper FRD development. 
 
2.1.3?Epigenetics?and?genomic?imprinting?
 
The epigenetics phenomenon was suggested in 1942 by Conrad Waddington as a 
mechanism causing heritable alterations in gene function (expression) which do not involve 
changes in DNA sequence. There are three distinct forms of epigenetic regulation, namely 
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DNA methylation, histone modification and non-coding RNA (reviewed in Inbar-Feigenberg 
et al. 2013). This review discusses DNA methylation and imprinting. 
DNA methylation is the most studied epigenetic phenomenon to date and involves cysteine 
methylation by DNA methylatransferase (DNMT) at cytosine-guanine dinuclotides (CpGs) in 
differentiated cells (Chen et al. 2011). Approximately 30 million CpG sites are found in the 
human genome, i.e. they cover about 1% of the genome (Fouse et al. 2010). The CpG sites 
are primarily located in GC rich promoter regions of genes, where, in general, a low level of 
DNA methylation means transcriptional activity of the gene and a high level of DNA 
methylation means gene silencing (reviewed in Inbar et al. 2013). 
 
Genomic imprinting occurs during early development and is an epigenetic phenomenon, 
where only one parental allele of a gene is expressed and the other is silenced. The 
regulation of genomic imprinting is through epigenetic mechanisms, which involves 
differential DNA methylation at so called differentially methylated regions (DMRs). DMRs 
are defined as either germline DMRs, where methylation is inherited from the male or 
female gamete and is maintained throughout development, or tissue-specific DMRs, at 
which  the  parental-specific  methylation  mark  is  set  after  fertilization.  DMRs  act  as  
imprinting control regions (ICRs) regulating the parental-of-origin manner of gene 
expression of one or several imprinted genes (John et  al. 1996, Inbar-Feigenberg et  al. 
2013). 
 
Genetic factors are considered the major player in human disorders, but epigenetic factors 
(epimutations) are known to also contribute. Epimutations may alter gene expression, 
leaving the DNA sequence intact. Moreover, they can be heritable through cell divisions, 
and are thereby good candidates for explaining the etiology of some disorders or aberrant 
phenotypes. Lynch syndrome, a form of hereditary nonpolyposis colon cancer (HNPCC) was 
one of the first examples where epimutations, namely in the DNA mismatch repair gene 
MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)), were associated with 
cancer susceptibility (Gazzoli et al. 2002,  Peltomaki  2012).  Another  example  is  the  
congenital Silver-Russell syndrome (SRS), a growth restriction syndrome, where 
hypomethylation of the ICR of the H19 gene is the major cause of the disorder (Penaherrera 
et al. 2010). Interestingly, SRS patients with skeletal and urogenital malformations as well as 
MA have been reported, suggesting a role for epimutations in MA (Bliek et al. 2006, Bruce et 
al. 2009). 
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2.1.4?Abnormalities?of?the?female?reproductive?duct?
 
Congenital malformations of the FRD are thought to arise during early embryogenesis and 
often occur in conjunction with specific syndromes, where FRD abnormalities are one 
symptom among many (Table 2). 
 
Table 2. Syndromes associated with malformations of the FRD. 
Syndrome Phenotype FRD status Cause OMIM1 
Reference  
Al-Awadi/Raas-
Rothschild 
severe malformations of 
upper limbs, hypoplastic 
pelvis, abnormal 
genitalia 
MA Autosomal 
recessive WNT7A 
mutation 
276820 
(Al-Awadi et 
al. 1985) 
Androgen 
insensitivity 
(testicular 
feminization) 
females with 46,XY, 
female external 
genitalia, breast 
development, 
abdominal testes and  in 
some cases no pubic 
and axillary hair 
MA X-linked recessive, 
androgen receptor 
(AR) mutation 
300068, 
312300 
Bardet-Biedl Ciliopathy,  renal 
abnormalities 
occasionally 
vaginal atresia, 
MA 
genetically 
heterogeneous 
209900 
CATCH22 
(22q11 deletion) 
parathyroid hypoplasia, 
cardiac malformations, 
cleft palate 
occasionally 
MA 
22q11.2del 
(TBX1 haplo-
insufficiency) 
188400 
(Sundaram et 
al. 2007) 
Cat-eye Coloboma of iris, heart 
and renal defects, other 
malformations 
occasionally 
MA 
22q11 115470 
(Schinzel et al. 
1981) 
Hand-Foot-
Genital 
small feet with short 
great toes, abnormal 
thumbs 
genital tract 
duplication 
HOXA13 mutation 140000 
Silver-Russel 
(SRS) 
growth retardation, 
craniofacial features, 
variable malformations 
occasionally 
MA 
H19 ICR1 
hypomethylation 
(20-60%); 
matUPD72 (10%) 
180860 
(Bliek et al. 
2006, Bruce et 
al. 2009) 
Tetraamelia tetraphocomelia, 
craniophacial 
abnormalities 
urogenital 
malformations 
Autosomal 
recessive, one 
family with WNT3 
mutation 
273395 
(Niemann et 
al. 2004) 
Thrombocyto-
penia absent 
radius (TAR) 
low platelet count, 
absence of radius 
occasionally 
MA 
1q21.1 
 
274000 
(Klopocki et 
al. 2007) 
Urogenitaladysp
lasia (hereditary 
renal dysplasia) 
Lethal renal 
abnormalities 
occasionally 
MA 
22q13.31 
UPK3A, PAX2, RET 
mutations 
191830 
MA = Müllerian aplasia 
1OMIM  (Online Mendelian Inheritance in Man) phenotype accession number. 
2matUPD7 = maternal uniparental disomy of chromosome 7 
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2.2?Müllerian?aplasia?
2.2.1?Definition?and?diagnosis?
 
Müllerian aplasia (MA) is defined as congenital aplasia of a functional uterus and vagina with 
normal female karyotype (46,XX) and secondary sexual characteristics, and usually normal 
functioning ovaries (Griffin et al. 1976, Simpson 1999). MA is mostly diagnosed in puberty 
when adolescent females are referred to a gynecologist due to primary amenorrea (no 
menstruation). Pubic and axillary hair growth is normal, as well as the external genitals, but 
instead of a normal-length vagina only a vaginal pouch extending approximately 1-3 cm is 
present.  Ultrasonography is used to detect the status of the uterus, the Fallopian tubes and 
the ovaries, and the finding is often confirmed by magnetic resonance imaging (MRI), less 
often by laparoscopy. Karyotyping is performed to exclude chromosomal abnormalities as a 
cause of the disorder. Hormonal levels (FSH, LH, estradiol and progesterone) are measured, 
if clinical signs of acne or hirsutism appear.  
 
According  to  a  population-based  study  in  Finland,  the  incidence  of  MA  is  at  least  1:5000  
female births (Aittomäki et al. 2001) and approximately the same worldwide (Griffin et al. 
1976, Folch et al. 2000, Morcel et  al. 2007).  MA  is  also  referred  to  as  MURCS association 
(Müllerian duct aplasia, Renal dysplasia and Cervical Somite anomalies, OMIM 601076), 
because renal and skeletal malformations occur in 20-40% of the patients. The 
malformations are mostly minor including renal aplasia, horseshoe kidney, scoliosis and 
milder vertebral defects (Griffin et al. 1976, Carson et al. 1983, Simpson 1999, Pittock et al. 
2005). Hearing defects (Letterie et al. 1991, Strubbe et al. 1994), cardiac malformations 
(Gilliam et al. 2002, Kula et al. 2004) and digital anomalies (Strubbe et al. 1987, Massafra et 
al. 1988)  have  been  reported  in  some  MA  cases.  Reports  of  MA  patients  with  associated  
anorectal malformations (Gilliam et al. 2002, Wester et al. 2012) or with a uterus (Doyle et 
al. 2009) exist, but these characteristics are not compatible with the clinical definition of MA 
(Jones 2006). 
 
The most common form of MA is the Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, 
with its name originating from the four clinicians who originally described the characteristics 
of MA; namely August Franz Joseph Mayer, Carl Freiherr von Rokitansky, Hermann Küster, 
and G. A. Hauser. In MRKH, remnants of the uterine cornu are present and connected by a 
thin streak of connective tissue (Figure 3). The Fallopian tubes are also present on one 
(unilateral) or both sides (bilateral).  MRKH is a heterogeneous group of phenotypes, which 
can be further divided into subtypes depending on the status and symmetry of Fallopian 
tubes, uterine remnants and ovaries. Some studies define patients as either typical (type A, 
type I or isolated) including patients with only genital malformations, or atypical (type B or 
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II) including patients with genital malformations and associated characteristics of MURCS 
(Strubbe et al. 1993, Oppelt et al. 2006). Depending on the diagnostic method used 
(laparoscopy, ultrasound, X-ray or magnetic resonance examination) and the amount of 
clinical data available, the patients cannot always be classified into A or B and are so-called 
unspecified  MRKH.  A  new  classification  system  called  VCUAM  (Vagina,  Cervix,  Uterus,  
Adnexa and associated Malformations), where malformations can be assigned to the precise 
organ subgroup, has been proposed in order to provide a clinical classification that more 
precisely reflects the entire genital malformation (Oppelt et al. 2005a). Within this study, all 
three types of MRKH (type A, B and unspecified) are classified as MA. The rarest form of MA 
is total MA, where all Müllerian derivatives (uterus, Fallopian tubes and upper vagina) are 
missing (Figure 3) (Griffin et al. 1976).  
 
Figure 3. Illustration of the female reproductive duct in a a) normal  female structure, b) MRKH and 
c) total Müllerian aplasia (MA) patient. Figure modified from Wikimedia 
(http://commons.wikimedia.org/wiki/File:Scheme_female_reproductive_system-en.svg). 
 
MA as the main phenotype in an otherwise healthy woman can be referred to as non-
syndromic. MA can also occur in conjunction with other syndromes and is then often 
referred to as syndromic MA. Examples of syndromes associated with MA are presented in 
Table 2. It is not clear if the same genetic variations could underlie both syndromic and non-
syndromic forms of MA. This thesis, however, is focused on the non-syndromic form of MA. 
 
In conjunction with the structural abnormalities of MA, it is important to note the 
psychosocial elements of the disorder. MA is mostly diagnosed in adolescence, at the age of 
14-16 years, in the period of transition from childhood to adulthood. It is a sensitive period 
in development, when the body as well as the mind is going through many changes and self-
esteem is forming. The diagnosis of MA, to be found without uterus and normal vagina with 
associated infertility is profoundly traumatizing. This diagnosis, at such a vulnerable age, 
must have a large impact on a girl´s life. Questions, such as how is normal sex life possible, 
will the structural abnormality hinder finding of a spouse and establishing a family, are all 
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relevant issues to a woman with MA.  All these aspects make MA one of the most difficult 
congenital female reproductive disorders to deal with. 
2.2.2?Treatment?
 
The vaginal aplasia in MA patients can be treated by nonsurgical or surgical methods.  
Timing for treatment is best planned when the patient is emotionally mature and desires 
correction. The first-line method in Finland and several other countries is the nonsurgical so 
call Frank´s method (Frank 1938, Committee on Adolescent Health Care 2013). It is based on 
dilation of the vagina from its original length (1-3 cm) until about 10 cm, which is considered 
normal for sexual intercourse. The dilation is done by the patient herself, using a series of 
dilators with growing size.   The method requires personal engagement of the patient, with 
daily  self-dilation  for  30  minutes  to  2  hours  for  several  months  to  years.  However,  
complications associated with surgery can be avoided when using this method (Laufer 2002, 
Committee on Adolescent Health Care 2013). The success rate of achieving an anatomically 
functioning vagina using vaginal dilation in highly motivated patients is reported to be 90-
95% (Roberts et al. 2001, Edmonds et al. 2012). Surgical methods are available for patients 
who are unsuccessful with dilators or for other reasons prefer this alternative. All methods 
are based on creation of a neovagina either by using skin or peritoneum implantation (e.g. 
William´s  and  Davydov´s  method),  small  bowel   or  by  gradual  mechanical  stretching  of  
vaginal pouch using a traction device (Vecchietti´s method), followed by use of vaginal 
dilators post-operatively. The surgical methods can be painful with risk of scarring and 
incontinence among other complications (Committee on Adolescent Health Care 2013, Pizzo 
et al. 2013). 
 
For the infertility, the only existing treatment is surrogacy.  Utilizing in vitro fertilization (IVF) 
surrogacy enables MA patients to have their own biological children with their spouse as 
they usually have normal functioning ovaries (Beski et al. 2000). At present, the legislation 
does not allow this treatment in many countries, Finland being among those. An initiative 
from the National Advisory Board on Social Welfare and Health Care Ethics (ETENE, 
http://www.etene.fi/en) concerning surrogacy treatment in Finland has been put forward to 
the Ministry of Justice in order to allow women infertile due to absence of uterus to have 
surrogacy. Uterus transplantation would be another possibility for infertility treatment. To 
date these procedures have been unsuccessful, and would require an immense amount of 
research and ethical discussion in order to become a realistic options for the patients 
(Brannstrom 2013, Del Priore et al. 2013). Even more far-reaching is the possibility of 
artificial wombs, by which the embryo would grow and develop outside of the human body 
in an artificial uterus (Bulletti et al. 2011). 
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2.2.3?Genetic?background?
 
Pattern of inheritance 
Most MA patients are sporadic cases, but familial occurrence has also been documented 
and affected sib-pairs have been reported in several publications (Jones et al. 1972, Griffin 
et al. 1976, Shokeir 1978, van Lingen et al. 1998, Morcel et al. 2007, Gervasini et al. 2010). 
Based on a study in Saskatchewan with 16 families, where several female family members 
were affected with different degrees of MA whereas the males showed no deleterious 
effects, a sex-limited autosomal dominant inheritance pattern was suggested (Shokeir 
1978). However, other studies were not able to support this mode of inheritance (Carson et 
al. 1983, van Lingen et al. 1998). 
 
Additionally, in the study by Petrozza et al. including 34 surrogate pregnancies, with oocytes  
from women with MA , 17 baby girls and 17 baby boys were born, of which all were healthy, 
except one male child with a middle ear defect.  None of the girls had MA, making it rather 
unlikely that the disorder would be caused by a single dominant mutation (Petrozza et al. 
1997). The most logical explanation for MA is a multifactorial or polygenic inheritance, 
which  in  rare  traits  such  as  MA  would  have  a  low  recurrence  risk  (1-2%)  for  first-degree  
relatives. However, in some instances or certain populations, a dominant or recessive mode 
of inheritance is possible (Simpson 1999). 
 
Candidate genes 
Several candidate genes have been suggested for MA. Most of these genes are members of 
the AMH, HOXA or WNT pathways, or other known genes with crucial roles during early 
development of the female urogenital structures. AMH, which is of interest due to its role in 
MD regression in males (Behringer et al. 1994),  and  its  receptor  AMHR2 were primarily 
investigated in MA patients, but no mutations were found (Resendes et al. 2001, Zenteno et 
al. 2004, Oppelt et al. 2005b). Candidate gene studies including HOXA7, HOXA9, HOXA10, 
HOXA11 and HOXA13, which are all required for successful MD formation, were also 
negative (Karnis et  al. 2000, Timmreck et al. 2003, Burel et  al. 2006, Lalwani et  al. 2008, 
Dang et al. 2012, Ekici et al. 2013). Mutation screening efforts in MA patients involving WT1 
(van Lingen et al. 1998), the retinoic acid nuclear receptors RARG and RXRA (Cheroki et al. 
2006), ?-catenin (CTNNB1) (Drummond et al. 2008), PBX1 (Ma et  al. 2011), PAX2 (Burel et 
al. 2006, Wang et al. 2012) DLGH1 and LAMC1 (Ravel et al. 2012) were also unable to find 
pathogenic gene variations. 
 
Contradictory results regarding a possible association between decreased levels of the 
galactose-1-phosphate uridyl transferase (GALT) enzyme and MRKH have been reported 
(Cramer et al. 1996, Klipstein et al. 2003, Zenteno et al. 2004). Cramer et al. reported a GALT 
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N314D mutation in 6/13 (46%) MRKH patients compared to 16/113 (14%) controls. The 
authors argued that decreased maternal or fetal GALT expression  due  to  the  N314D  
mutation could result in vaginal agenesis (Cramer et al. 1996). However, two other studies 
in 15 and 32 MA patients, respectively, failed to replicate these results, thereby suggesting 
that decreased GALT expression does not associate with MA (Klipstein et al. 2003, Zenteno 
et al. 2004). The carrier frequency of the N314D variation has been reported as high in 
controls in other studies (Morland et  al. 1998, Stefansson et  al. 2001) and the association 
Cramer et al. found might therefore be due to their low patient number (Zenteno et al. 
2004).  
 
The first positive finding of a mutation in a patient with MA was reported in 2004. Biason-
Lauber and coworkers screened WNT4 in a girl with MRKH and unilateral renal agenesis 
(Biason-Lauber et al. 2004). They found a heterozygous loss-of-function mutation (E226G) 
situated in exon 5 of the gene (Figure 4). The mutation was shown to prevent correct lipid 
modification. The mutant molecule was less hydrophobic than the normal one, and thereby 
trapped in the cell. The decreased WNT4 expression resulted in impaired MD formation as 
well as elevated androgen production. The phenotype of the patient was strikingly similar to 
the mouse mutant model Wnt4-/- (Vainio et  al. 1999, Biason-Lauber et  al. 2004). Shortly 
after this report, three more heterozygous missense WNT4 mutations were reported in 
three patients with MRKH and androgen excess (Figure 4) (Biason-Lauber et al. 2007, 
Philibert et al. 2008, Philibert et  al. 2011). However, WNT4 mutations were not found in 
other cohorts of patients with the classical form of MRKH without androgen excess 
(Clement-Ziza et  al. 2005, Ravel et  al. 2009). Therefore, MRKH in conjunction with 
hyperandrogenism can be regarded as an entity of its own or as a rare subtype of MA 
(OMIM 158330) (Clement-Ziza et al. 2005, Biason-Lauber et  al. 2007).  Genetic  studies  of  
other WNT genes (WTN5A, WNT7A and WNT9B) in MA patients have been negative 
(Timmreck et al. 2003, Ravel et al. 2009, Dang et al. 2012). 
 
 
 
Figure 4: WNT4 mutations found in patients with MRKH and hyperandrogenism. The mutations are 
all heterozygous, nonsynonumous and located in exons 1 (L12P; Philibert et al. 2008), 2 (R83C; 
Biason-Lauber et al. 2007) and 5 (E226G; Biason-Lauber et al. 2004 and A233T; Philibert et al. 2011) 
of the gene. Figure modified from Biason-Lauber et al. (2004). 
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Recently, mutations in another gene, LHX1, were observed in two patients with MA (Ledig et 
al. 2011, Ledig et al. 2012).  The mutations were a missense mutation in exon 4 (p.R264G) 
and a heterozygous adenine duplication at position 25 in exon 1, leading to a frame shift 
and premature stop codon at amino acid 33 (c.25dup; p.Arg9LysfsX25). The patient with the 
exon 4 mutation was reported as MRKH type I, whereas the patient with the exon 1 
mutation was reported as MRKH type II with unilateral renal agenesis, both largely 
resembling the Lhx1 mutant mouse phenotype with renal agenesis and absent uterus and 
oviducts (Kobayashi et al. 2004). LHX1 is  a  member  of  the  LIM  homeodomain  TF  family  
containing two LIM domains, a central homeodomain possessing DNA-binding activity and a 
transactivation domain at the C-terminus (Bozzi et al. 1996). Downstream targets of LHX1 
have not been reported to date (Ledig et al. 2012). In mouse, Lhx1 expression starts in the 
MD epithelium at E11.5 in both sexes. In females, the expression persists at least until 
E16.5,  whereas  in  males  it  starts  to  weaken  at  E14.5  corresponding  to  the  ongoing  MD  
regression (Kobayashi et al. 2004). 
 
Presence of TSPY1 in  patients  with  MA  has  also  been  suggested  to  play  a  part  in  the  
development of MA. This is primarily based on a study by Plevraki and coworkers, where 
four out of six MA patients were reported to carry fragments of TSPY1 (Plevraki et al. 2004). 
TSPY1 has been suggested as a candidate gene for gonadoblastoma and to have a 
proliferative role in spermatogenesis (Lau et al. 2009). 
 
Copy number variations 
Several CNVs (microdeletions or microduplications) have been reported in association with 
MA  (Table  3).  Most  of  these  are  rare,  observed  only  in  one  or  two  patients  and  have  not  
been reported in the Database of Genomic Variants (DGV). Therefore, their importance in 
the etiology of MA is inconclusive. However, four chromosomal regions, 1q21.1, 16p11.2, 
17q12 and 22q11.2, stand out from the rest because they have been found in three, four, 
nine and six patients, respectively (Cheroki et al. 2006, Klopocki et al. 2007, Sundaram et al. 
2007, Cheroki et al. 2008, Bernardini et al. 2009, Ledig et al. 2011, Nik-Zainal et al. 2011). 
 
1q21.1 is a known locus for TAR (OMIM 274000) characterized by reduction of platelet 
number and absent radius (a bone in the forearm) and two TAR patients were reported with 
MA (Klopocki et al. 2007, Ledig et al. 2011).  One patient with complete uterine and vaginal 
aplasia in conjunction with fused external labia and undetected ovaries by ultrasound was 
reported with CNVs in the TAR locus and 22q11.22 (Cheroki et al. 2008). The 22q11.2 locus 
is known for DiGeorge (OMIM 188400), velocardiofacial (OMIM 192430) and 22q11.2 distal 
deletion syndrome (Ben-Shachar et  al. 2008) characterized by a variable phenotype 
including facial dysmorphic features, congenital heart defects and behavioral difficulties. 
Four patients were reported with 22q11.2 deletion and MA (Cheroki et al. 2006, Sundaram 
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et al. 2007, Cheroki et al. 2008, Nik-Zainal et al. 2011), whereas one MA patient was 
reported with duplications in 22q11.21 and 12q23.1 (Ledig et al. 2011). 
 
Table 3. Summary of copy number variations (CNVs) detected in patients with MA. 
Locus CNV Size Patients Phenotype Reference 
1q21.1 del ~0.5 Mb 2 TAR, MA Klopocki et al. 2007, Ledig 
et al. 2011 
1q21.1 and 
22q11.22 
dup 
dup 
2.7 Mb 
0.6 Mb 
1 syndromic MA Cheroki et al. 2008 
2q11.2 dup 1.30 Mb 1 MA Nik-Zainal et al. 2011 
2q13 and 
17q12 
del 
del 
0.1 Mb 
1.4 Mb 
 MA Ledig et al. 2011 
3p21.31 dup 0.1 Mb 1 MA Ledig et al. 2011 
4q34?qter del ND 1 MAa Bendavid et al. 2007 
4q32.2 del 0.34 Mb 1 MA Ledig et al. 2011 
4q28.3 del 0.1 Mb 1 MA Ledig et al. 2011 
6p21.2, 
6q25.1 and 
6q25.2 
dup 
dup 
dup 
0.2 Mb 
0.4 Mb 
0.4 Mb 
1 MA Ledig et al. 2011 
10q24.33 dup 56 kb 1 MA Ledig et al. 2011 
12q23.1 and 
22q11.21 
dup 
dup 
0.1 Mb 
0.4 Mb 
1 MA Ledig et al. 2011 
12q24.12 and 
Xp11.3 
dup 
dup 
0.1 Mb 
0.2 Mb 
1 MA Ledig et al. 2011 
16p11.2 del ~0.55 Mb 4 MA Nik-Zainal et al. 2011 
17q12 del 1.4 Mb 4 MA Nik-Zainal et al. 2011 
17q12 del 1.5 Mb 2 MA, one with mild 
dysmorphism, one with 
renal cysts 
Bernardini et al. 2009 
17q12 del 1.8 Mb 1 MA Ledig et al. 2011 
17q12 del 1.2 Mb 1 syndromic MA (mental 
imparement) 
Cheroki et al. 2008 
22q11.2 del 0.39 Mb 1 22q11.2 distal 
syndrome, MA 
Nik-Zainal et al. 2011 
22q11.2 del ND 2 22q11.2 syndrome, MA Sundaram et al. 2007 
22q11.21 del 2.6 Mb 1 22q11.2 syndrome, MA Cheroki et al. 2006, 
Cheroki et al. 2008 
Xp11.1 del 0.1 Mb 1 MA Ledig et al. 2011 
Xp22.2 dup 0.4 Mb 1 MA Ledig et al. 2011 
Xq21.31 del 1 Mb 1 syndromic MA Cheroki et al. 2008 
a mother had the same deletion but not MA, instead cardiac defect and Fallopian tube cancer 
ND=no data; TAR= thrombocytopenia, absent radius 
 
Four MA patients without features of other syndromes were recently reported with 
deletions of 16p11.2 (Nik-Zainal et al. 2011),  a  CNV  previously  documented  in  association  
with autism (Kumar et  al. 2008, Weiss et al. 2008), schizophrenia (McCarthy et al. 2009), 
developmental delay (Rosenfeld et al. 2010) and obesity (Walters et  al. 2010). 17q12 
deletions have been reported in six MA patients without additional syndromes (Ledig et al. 
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2011, Nik-Zainal et al. 2011) and in three MA patients with either renal cysts, mild 
dysmorphic features (Bernardini et  al. 2009) or mental impairment (Cheroki et  al. 2008). 
CNVs in 17q12 have previously been associated with several phenotypes including renal 
malformations and cysts, growth restriction, speech problems (Mefford et  al. 2007, 
Nagamani et al. 2010) and autism (Loirat et al. 2010). The 17q12 region includes LHX1 and 
HNF1?, for which mutations were described in 4/63 MA patients (Ledig et al. 2011, Ledig et 
al. 2012) and in 2/4 patients with mild diabetes and MA (Lindner et al. 1999), respectively. 
 
 
Partial duplications of the short stature homeobox (SHOX) gene have been reported in five 
MA patients (two sporadic, three familial). Two sisters carried the same duplication 
inherited from their unaffected father, whereas two healthy sisters and their healthy 
mother did not have the duplication (Gervasini et  al. 2010). SHOX is a homeobox gene 
located on the pseudoautosomal region (PAR1) of the X (Xp22) and Y (Yp11.3) 
chromosomes. Mutations and CNVs in SHOX have previously been associated with 
idiopathic short stature (ISS, OMIM 300582), Turner syndrome, dyschondrosteosis (Leri-
Weill syndrome, LWD, OMIM 127300) and Langer mesomelic dysplasia (OMIM 249700) 
(Ellison et al. 1997, Belin et al. 1998, Shears et al. 1998, Rao et al. 2010, Benito-Sanz et al. 
2011). 
 
Epigenetic factors and expression studies 
DNA hypomethylation of the imprinting control region ICR1 of H19 has been associated with 
genital and skeletal malformations in Silver Russel syndrome (SRS) patients (Bliek et  al. 
2006).  Two  SRS  patients  with  extreme H19 ICR1 hypomethylation and MA have been 
described (Bruce et al. 2009), thereby suggesting a role for epigenetic factors in the etiology 
of MA. Reports of monozygotic twins where one twin is healthy and the other has MA also 
suggest the possibility of epigenetic involvement (Lischke et al. 1973, Steinkampf et al. 2003, 
Duru et al. 2009). The surrogate pregnancies with oocytes from MA women resulting in only 
healthy baby girls (Petrozza et al. 1997) also argue for possible epigenetic regulation or 
epimutation in the development of the disorder. 
 
One study including genome-wide methylation and expression data from patients with MA 
has been published. This combined methylome and transcriptome study was based on 
uterine remnant tissue from seven and eight MA patients, respectively. The study revealed 
nine genes relevant for FRD development that were both differently methylated and 
differently expressed in patient compared to control samples. Based on these results, the 
authors suggest GATA binding protein 4 (GATA4) and WT1 as well as the estrogen receptor 1 
(ESR1) as good candidate genes for further studies (Rall et al. 2011). From mouse studies 
Gata4 and Wt1 were  shown  to  form  a  complex  that  synergistically  binds  to  the  sex  
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determining gene Sry as  well  as  to the Amh promoter, thereby affecting the expression of 
AMH responsible for MD regression (Miyamoto et al. 2008). Estrogens, on the other hand, 
are important for normal uterine development. Mutant mouse models have hypoplastic 
uterus and vagina, illuminating a role for the gene in normal FRD development (Couse et al. 
1999).  The HOXA gene pathway was also highlighted as relevant for FRD development, 
because both HOXA5 and HOXA9 showed aberrant expression in MA patients compared to 
control samples (Rall et al. 2011). 
 
Teratogens 
Teratogens are reagents or factors that can cause developmental defects when the fetus is 
exposed to these substances. Diethylstilbestrol (DES) is a known teratogen and an endocrine 
disrupting chemical that was frequently prescribed to pregnant women during the 1940s to 
the 1970s to prevent miscarriage. However, DES was found to have both teratogenic and 
oncogenic effects on many organs, including the male and female reproductive systems, 
when exposure occurred in utero. DES might not directly affect the formation of the MDs, 
but from mouse models it is known that DES affects several genes in the Wnt and Hoxa gene 
pathways, thereby affecting FRD development (Ma 2009). 
 
2.3?Genetic?methods?for?studying?Müllerian?aplasia?
 
The human genome comprises approximately 3 billion base pairs (bp) of deoxyribonucleic 
acid (DNA) tightly packed into 23 pairs of chromosomes (22 pairs of autosomes, one pair of 
sex  chromosomes)  in  each  cell  of  an  individual  excluding  germ  cells.  An  immense  
international research effort, the Human Genome Project (HGP) aiming at determining the 
entire DNA sequence of the human genome and identifying all human genes, was 
completed in 2003 with the first draft of the genetic structure of the human genome 
published in 2001 (Lander et al. 2001)  and  a  more  detailed  version  in  2007  (Levy et al. 
2007). The number of genes transcribed from the human genome and translated into 
functional proteins is estimated to be 20-23 000, much lower than anticipated. However, 
the noncoding parts of the genome are thought to harbor many regulatory and biochemical 
functions still to be elucidated. The genes are divided into coding units, exons, and 
noncoding units, introns. By differential splicing of the introns, several protein products with 
different lengths and functions and differing time windows of expression can be created. 
One of the basic features of the human genome is sequence variability between every 
individual,  which  is  estimated  to  occur  in  one  base  pair  per  every  1000  nucleotides  (The  
International HapMap Consortium 2005, Ng et al. 2008). 
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2.3.1?Genome-wide?approach?
 
Genome-wide approaches are often the starting point for finding genomic variations 
associated with a given disorder. Genome-wide approaches include array-based platforms 
utilizing DNA or RNA as the starting material for studying genetic differences. 
 
In MA, array comparative genomic hybridization (aCGH) has been utilized for genome-wide 
identification of CNVs (microdeletions or microduplications) that might associate with the 
disorder. This method can identify much smaller changes (within an individual gene) than 
the classical karyotyping using differently labeled patient and  control samples hybridized 
against up to millions of probes located throughout the genome. The higher the frequency 
of the probes, the better the sensitivity, coverage and specificity in defining the start and 
end points of CNVs. 
 
CNVs can also be studied using single nucleotide polymorphism (SNP) genotyping and 
multiplex ligation-dependent probe amplification (MLPA). SNPs are single-base changes in 
the DNA and the most common form of variation in the genome. Successive SNP deletions 
or duplications are indicative of a larger genomic aberration (CNV). SNP genotyping is 
commonly used for comparing genotype frequencies between patients and controls. Since 
MA  patients  are  mostly  sporadic  cases,  family  studies  are  rarely  possible.  MLPA  is  a  
multiplex method for detecting intragenic CNVs, i.e. gain or loss of exons or entire genes, 
especially suitable for small-scale screening. MLPA has been used successfully also in MA 
studies (Gervasini et al. 2010). 
 
Gene expression studies based on tissue-extracted RNA are troublesome in MA, because we 
are investigating a “missing” tissue. However, in one study the remnants of the uterus were 
collected in laparoscopy-assisted surgery for neovagina construction. DNA extracted from 
the same specimens was used for genome-wide DNA methylation studies (Rall et al. 2011). 
 
Over the past years, next-generation sequencing (NGS) methods have emerged and taken a 
leader position in finding disease-causing genes. Exome sequencing, i.e. sequencing of all 
protein-coding genes in the genome, is widely used and has been a successful approach in 
finding the underlying cause for both monogenic and complex disorders. Whole-genome 
sequencing is more challenging with an enormous amount of data produced. The statistical 
analyses are laborious, especially when studying multifactorial disorders (Bamshad et  al. 
2012). Studies in MA patients utilizing NGS methods have not yet been published. 
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2.3.2?Candidate?gene?approach?
 
Candidate genes are usually chosen based on previous knowledge of metabolic pathways or 
animal models. In MA, the first candidate studies were based on genes known to affect FRD 
development from mouse knockout studies. Thus far, all have been negative, except for 
WNT4 (reviewed in section 2.2.3). 
Another candidate gene approach is to study genes located within CNV regions known to 
associate  with  MA.  Within  these  CNV  regions,  genes  previously  known  to  be  important  in  
mesodermal or early embryonic development have been chosen for further screening. With 
this approach, LHX1 mutations within the 17q12 deletion region were found in women with 
MA (reviewed in section 2.2.3). 
2.3.3?Mutation?screening?
 
When a candidate gene of interest has been selected, the next step is to screen for 
nucleotide changes i.e. mutations primarily in the protein-coding DNA sequence segregating 
with the disease-phenotype, and not found in a selected set of healthy control samples. 
Polymorphisms, which are nucleotide changes common in the population and not disease-
associated, are important to rule out. 
 
By Sanger sequencing different types of mutations can be found. A point mutation is a 
change of one nucleotide in the DNA sequence, through a single base substitution, deletion 
or insertion. A silent or synonymous mutation is a point mutation, which does not alter the 
encoded amino acid and therefore has no effect on the protein function. However, a silent 
mutation can have a pathogenic effect if located in a functionally important part of the 
gene. A nonsynonymous or missense mutation is a point mutation where the nucleotide 
substitution causes an amino acid change. Missense mutations can be rare polymorphisms, 
but are more likely to be pathogenic if they occur in a highly conserved base or amino acid, 
or in a functionally important gene region. A nonsense mutation is  a  point  mutation  that  
introduces a premature stop codon in the transcript. Depending on the site in which it 
occurs, a nonsense mutation can result in a shortened non-functional protein product 
(Strachan et al. 2004). Frameshift mutations are caused by deletions, duplications or 
insertions of one or more nucleotides in the protein-coding DNA sequence. These can result 
in a disrupted reading-frame, also with a shortened non-functional protein product as the 
end result. A splice-site mutation is a nucleotide change occurring intronically in the highly 
conserved splice donor site, branch site or splice acceptor site at either 5´ or 3´end of an 
exon. The mutation causes incorrect splicing of the following exon, often resulting in a 
premature stop codon and a shortened non-functional protein product (Strachan et al. 
2004). 
 
 
33 
 
 
3. Aims?of?the?study?
 
The aim of this doctoral thesis was to investigate the genetic background of MA.  
The following specific aims were set for the study: 
 
I. To determine if Y chromosomal genetic material and in particular the earlier 
reported TSPY1 fragment is found in Finnish MA patients. 
II. To investigate MA patient DNA methylation status of the H19 ICR1 region on 
11p15 known to be involved in growth and related developmental disorders. 
III. To evaluate SHOX CNVs as a cause of MA in Finnish patients. 
IV. To find new candidate genes for MA. 
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4. Patients?and?methods?
4.1?Patients?and?controls?
 
The Finnish MA project was initiated in the Helsinki University Central Hospital 
(HUCH)/Department of Obstetrics and Gynecology in the mid-1970s when clinical data 
collection from MA patients began.  Subsequently, detailed clinical data and blood samples 
were collected through all five university hospitals in Finland from 1978 to 1993. Since the 
end of the 1990s, the enrolment of MA patients has been ongoing at HUCH. In 2011, a new 
enrolment of MA patients was started through Oulu University Central Hospital and Turku 
University Central Hospital. 
 
To date, clinical data has been collected for 250 Finnish patients and two foreign patients 
originating from Russia and the Middle East. DNA samples are available from 140 patients 
and 36 relatives (29 mothers, 4 fathers and 3 healthy sisters from 31 families in total). 
Peripheral blood RNA samples have been collected from only a few patients. The majority of 
Finnish patients have the MRKH phenotype, while total aplasia comprises less than 10% of 
MA (personal communication, Minna Puhakka, M.D.) The majority of the MA patients are 
sporadic cases. However, one sibling pair with one sister having MRKH and the other having 
total MA was included in the study. Urinary tract malformations including renal defects 
occur in 24% of the patients and skeletal malformations in 48% of the patients (personal 
communication, Minna Puhakka M.D.). Considering that MA is a rare syndrome with an 
incidence of 1:5000 new born girls, the yearly number of girls born in Finland with this 
syndrome is around six. When considering the sensitivity of the syndrome, the collected 
sample set and its size in relation to the size of the Finnish population is remarkably large. 
To  our  knowledge  this  series  is  also  one  of  the  largest  MA  sample  sets  in  the  world.  A  
German research group recently published a clinical overview/retrospective study of a MA 
cohort, comprising 284 MRKH women, the largest cohort thus far published (Oppelt et al. 
2012). Molecular genetic studies of MA have mostly been performed in smaller cohort sizes 
including 1-63 patients (Biason-Lauber et al. 2004, Plevraki et al. 2004, Plevraki et al. 2004, 
Gervasini et al. 2010, Ledig et al. 2011, Nik-Zainal et al. 2011, Philibert et al. 2011). 
 
The  control  group  consisted  of  200  healthy  Finnish  females  with  at  least  one  normal  
pregnancy. The blood samples were collected at the HUCH. Five healthy male controls were 
obtained from the Finnish Red Cross for validation of Study I. Detailed data on the number 
of patients and controls included in each study are given in Table 4. 
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Table 4: Number of MA patients, healthy relatives, and controls included in each study. Study II  
and IV include methods for which the investigated number of patients and controls differs from the 
total number (shown in brackets). 
 
Study Patients Healthy 
relatives 
Healthy controls 
I 110 20a 105b 
II 83 (80 in qPCR; 38 in HM27) - 20 (6 in HM27) 
III 101 - 115 
IV 112  (50  in  aCGH;  12  in  SNP  
genotyping; 6 in qPCR; 3 in RT-PCR) 
- 200 (100 in MLPA; 150/180 for LHX1 
studies; 6 in qPCR; 3 in RT-PCR) 
a 13 mothers, 4 fathers, and 3 sisters from different families. 
b five of the controls are healthy males from the Finnish Red Cross 
HM27=Genome-wide Infinium HumanMethylation27 Bead Arrays 
 
4.2?Ethical?issues?
 
Informed consent was obtained from all participants prior to enrolment in the study. For 
patients <18 years, signed consent was also obtained from the guardian. The study protocol 
has been approved by the Finnish Ministry of Social Affairs and Health and reviewed by the 
Ethics Committee of the Department of Obstetrics and Gynecology of the HUCH. 
4.3?Methods?
 
A summary of all methods used in this thesis project is included in Table 5. The most 
relevant methods are separately summarized in the following sections. 
 
Table 5. Summary of used genetic methods. 
 
Method Used in Study 
DNA extraction from peripheral blood I, II, III, IV 
RNA extraction from peripheral blood IV 
Polymerase chain reaction (PCR) I, II, III, IV 
Real-time quantitative polymerase chain reaction (q-PCR) II 
Reverse transcriptase-PCR (RT-PCR) IV 
Gel electrophoresis I, II, III, IV 
Sanger sequencing I, II, III, IV 
Multiplex ligation-dependent probe amplification (MLPA) III, IV 
Genome-wide DNA methylation microarrays II 
Comparative genomic hybridization (aCGH) IV 
Genome-wide single-nucleotide polymorphism (SNP) genotyping IV 
?
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4.3.1?Extraction?of?DNA?and?RNA?from?peripheral?blood??
 
Genomic DNA was extracted from EDTA or heparin blood collection tubes with the 
Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN) including protein 
precipitation according to the manufacturer’s recommendation or by the phenol-chloroform 
method. DNA quality and quantity was analyzed by NanoDrop ND-1000 spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA, USA). Genomic RNA was extracted from PAXgene 
Blood RNA Tubes (PreAnalytiX Gmbh, Hombrechtikon, Switzerland) by the PAXGene RNA Kit 
(Qiagen, Hilden, Germany) according to the recommended protocol. The extracted RNA was 
further DNase-treated using the DNA-freeTM kit (Applied Biosystems, Foster City, CA, USA) to 
remove genomic DNA (gDNA). 
 
4.3.2?Polymerase?chain?reaction?
 
Polymerase chain reaction (PCR) is a well-established method for amplifying a large amount 
of a specific stretch of DNA, optimally 200-800 bp in length. Ph.D. Kary Mullis was 
acknowledged with the Nobel Prize in 1993 for the development of the method into an 
important biochemical technique. The DNA fragment of interest is enzymatically replicated 
by the use of short oligonucleotides (primers) complementary to the flanking region of the 
fragment and DNA polymerase through repeated series (thermal cycling) of heating, 
annealing, extension and cooling. Primers for the DNA fragments of interest were designed 
using different publically available software programs, such as Primer3 
(http://frodo.wi.mit.edu/primer3/input.htm) and ExonPrimer 
(http://ihg.gsf.de/ihg/ExonPrimer.html). The specificity of the primers was tested and 
sequence comparisons were performed using Ensembl 
(http://www.ensembl.org/index.html), UCSC (http://www.genome.ucsc.edu/cgi-
bin/hgGateway) or NCBI (http://www.ncbi.nlm.nih.gov/) Genome Browsers. Databases 
including known SNPs, e.g. dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/), the 1000 
Genomes database (http://browser.1000genomes.org/index.html) and Exome Variant 
Server (EVS, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA; 
http://evs.gs.washington.edu/EVS/), were used when designing optimal primers with high 
specificity. 
The PCR reactions in this study were run as single (Study I-IV), multiplex (Study I) or nested 
reactions (Study I). Real-time quantitative PCR (qPCR) assessing the specific amount of an 
amplified PCR product was used in Study II. Reverse transcriptase PCR (RT-PCR) was utilized 
in Study IV. RT-PCR enables PCR amplification of RNA through conversion of RNA into 
complementary DNA (cDNA) by a reverse transcriptase enzyme. Thereafter a standard PCR 
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reaction can be performed. RT-PCR is especially useful for investing the effects of gDNA 
mutations on the transcriptional (cDNA) level. 
The sizes of the amplified PCR products were determined by the use of gel electrophoresis 
and ethidium bromide or MidoriGreen DNA stain, which are intercalating agents used as 
fluorescent tags for nucleic acid binding. The PCR products were then further analyzed by 
traditional Sanger sequencing using an automated ABI3730XL DNA Analyzer (Applied 
Biosystems). 
4.3.3?Multiplex?ligation-dependent?probe?amplification?(MLPA)?
 
MLPA is a multiplex PCR method for determining the relative copy number of several DNA 
or RNA sequences at a time. In Study III we used the commercially available SALSA MLPA kit 
for SHOX (MRC-Holland, Amsterdam, Netherlands) CNV detection, whereas in Study IV we 
designed synthetic MLPA probes for TBX6 to detect intragenic deletions or duplications. The 
probe design has been described in detail in the Patients and methods’ section of 
publication IV. Each MLPA probe has a unique length, which can be detected using capillary 
electrophoresis and visualized by e.g. GeneMapper software version 4.0 (Applied 
Biosystems). Differences in relative copy numbers between the studied probes can be 
detected  using  MRC  Coffylazer  MLPA-Data  Software  (MRC-Holland)  or  using  a  calculation  
based method (summarized in the Patients and method-section of publication III and IV). 
4.3.4?Genome-wide?microarray-based?methods?
 
Several DNA-based microarray methods were used in this project to screen for genomic 
aberrations on a genome-wide level. Infinium HumanMethylation27 Bead Arrays (HM27), 
Illumina, San Diego, CA, USA) were used in Study II for studying DNA methylation. The 
technology  allows  single  CpG  resolution  of  >27,000  CpG  sites  using  500  ng  of  bisulphite-
converted DNA as starting material. Treatment of DNA by bisulfite (ZymoResearch, Orange, 
CA, USA) results in conversion of unmethylated cytosin (C) to uracil, leaving methylated 5-
methylcytosin unaffected, thus enabling detection of methylation status in patient versus 
control samples.  HumanOmni2.5-8 BeadChip v1.0 (Illumina) was used for single-nucleotide 
polymorphism (SNP) genotyping in Study IV. This technique enables high-resolution SNP 
detection of almost 2.4 million markers, both common and rare minor allele frequencies 
(MAF, >2.5%) according to 1000 Genomes Project data including CNVs, from 200 ng of DNA. 
Both array projects were performed by the Technology Centre, Institute for Molecular 
Medicine Finland (FIMM), University of Helsinki, Finland and the results were analysed by 
Genome Studio software (Illumina). 
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Comparative genomic hybridization (aCGH) arrays (180 K platform, Oxford Gene 
Technology, Yarnton, Oxford, UK) are widely used for high-resolution detection of CNVs 
(deletions or duplications) in the genome. The 180 K platform with genome-wide coverage 
and an overall median probe spacing of 13 Kb was used for CNV screening in Study IV, which 
was performed in collaboration with Érika Freitas, Ph.D., and Assistant Professor Carla 
Rosenberg, Ph.D., at the Institute of Biosciences, University of São Paulo, Brazil. Genomic 
Workbench software (Agilent Technologies, Santa Clara, CA, USA) was used for CNV calling. 
4.3.5?Statistical?methods?
 
Statistical t-tests (Kolmogorov-Smirnov (K-S) and Mann-Whitney U (M-W U), PASW Statistics 
18 software (SPSS, Chicago, IL) were used to test for the statistical significance of the 
findings. K-S can be used when assessing data sets showing normal distribution, whereas M-
W U is optimized for unequal data distribution. Therefore, K-S was utilized in Study II to 
assess the difference in methylation status in patients compared to controls for most of the 
H19 CpG sites, whereas M-W U was utilized in Study II to assess CpG sites showing unequal 
distribution, as well as to assess the methylation difference in the H19-HpaII site 25 
between patients and controls. In Study IV differences in SNP allele frequency between 
patients and controls were calculated using M-W U.  Correction for multiple testing adjusts 
p-values derived from the numerous statistical tests performed. This was performed using 
the conservative Bonferroni method in Study IV, and in Study II using the false discovery 
rate (FDR; www.r-project.org), which shows the expected proportion of false positives in the 
data.  
4.3.6?Freely?available?databases?
 
Several different freely available online databases were utilized throughout this thesis. In 
addition to those databases already mentioned, UniProtKB (http://www.uniprot.org/) was 
used for protein sequences and functional information and MutationTaster (Schwarz et  al. 
2010), PON-P (http://bioinf.uta.fi/PON-P/) including PhD-SNP 2.0.6, PolyPhen 2.0.22, SIFT 
4.0.3, SNAP 1.0.8 and I-Mutant 3.0.6 programs used for analysis, SpliceMan 
(http://fairbrother.biomed.brown.edu/spliceman/index.cgi), SplicePort 
(http://spliceport.cbcb.umd.edu/SplicingAnalyser.html) and Human Splicing Finder 
(http://www.umd.be/HSF/) software programs were used for in silico prediction of genetic 
variants. CpG Plot (http://www.ebi.ac.uk/Tools/emboss/cpgplot/) and CpG Island Searcher 
(http://www.uscnorris.com/cpgislands2/cpg.aspx) were used for identifying promoter 
regions. Database of Genomic Variants (DGV, http://projects.tcag.ca/variation) was used for 
information on structural variants of the human genome. Online Mendelian Inheritance In 
Man (http://www.omim.org/) is a freely available online catalogue including human genes 
and associated genomic disorders. 
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5. Results?and?Discussion?
 
5.1?The???chromosome?and?Müllerian?aplasia?(Study?I)?
 
In this study the focus was set to investigate if the Y chromosomal DNA, or more precisely, if 
presence of any Y chromosomal fragments in the genetic make-up of MA patients, could 
have an effect on the development of the disorder.  
 
We studied DNA from 110 Finnish MA patients and 20 healthy relatives for TSPY1 and  38  
additional  loci  covering  the  Y  chromosome  (Figure  5)  by  PCR  amplification  (single,  nested  
and multiplex reactions). The primer information and amplification protocols for 33 of the 
38  loci  (the  so  called  Y  panel)  were  acquired  from  the  HUCH,  Laboratory  of  Prenatal  
Diagnostics, where they were routinely used for male infertility screening. Five additional 
markers were designed within our study in order to improve the coverage of especially the 
short arm of the chromosome. 
 
 
 
 
Figure 5: Schematic view of the investigated loci and their locations on the Y chromosome 
(Sandbacka et al. 2009). PAR = pseudoautosomal region, AZF = Azoospermia Factor. 
 
All studied Y chromosomal fragments were absent in the Finnish female patients, indicating 
that the corresponding Y chromosomal regions are not the cause of MA in the investigated 
sample set. 
 
Presence of TSPY1 was  previously  suggested  as  the  primary  cause  of  MA  in  the  study  of  
Plevraki and colleagues (Plevraki et  al. 2004). Their result was based on positive 
amplification by nested PCR in 4/6 MA patients. Nested PCR involves a second round of PCR 
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amplification using a previous PCR product as starting material. This can increase the yield 
of  an amplicon that  is  only  vaguely,  if  at  all,  detected in the first  PCR round.  In our study,  
using the same PCR primers as Plevraki and colleagues, the nested PCR reactions for TSPY1 
amplification were unreliable resulting in false positive results due to unspecific binding of 
the primers. Similar observations were reported by Álvarez-Nava and coworkers, where 
positive amplification results alternated with negative ones, and two healthy female 
controls showed positive amplification (Alvarez-Nava et al. 2004). Therefore, we designed 
new primers specific only to TSPY1, which replaced the need for nested PCR, and performed 
single PCRs in all Finnish patients, 100 healthy females who all had biological children, 20 
healthy relatives (13 mothers, 4 fathers and 3 sisters) and five healthy males from the 
Finnish Red Cross as controls. All males (fathers and male controls) were positive for TSPY1, 
whereas all females (patients, female relatives and controls) were negative.  
 
In addition, to further investigate if any other fragments from the Y chromosome might be 
involved in the development of MA, we studied 38 additional Y loci. None of the female 
patients showed presence of any of the 38 studied fragments, whereas the male samples 
showed strong amplification of each of them. However, for a few markers some female 
samples (both patients and controls) generated PCR products, but these were not the same 
size  as  in  male  samples.  Repetitive  PCR  reactions  showed  inconsistent  results  indicating  
unspecific binding of the PCR primers, confirmed by Sanger sequencing. The reason for the 
unspecific binding is probably the highly repetitive DNA sequence structure of the Y 
chromosome, as well as a high frequency of shared genomic sequences between the X and Y 
chromosomes. 
 
During normal male development the Y-chromosomally expressed SRY activates AMH 
expression  from  the  testis  resulting  in  MD  regression.  Therefore,  if  fragments  with  Y-
chromosomal origin would be present in MA patients (46,XX), they could cause MD 
regression and the MA phenotype. In the study by Plevraki and coworkers (Plevraki et al. 
2004) four out of six MA patients were reported to carry fragments of the Y-chromosomal 
TSPY1 supporting above-mentioned hypothesis. However, in our study, which included 
almost 20 times more patients, none of the patients were positive for TSPY1 amplification 
by  PCR.  This  raises  the  question  of  the  reliability  of  the  results  from  the  Plevraki  group.  
TSPY1 has previously been suggested as a putative gene for gonadoblastoma (Lau et  al. 
2009) and TSPY1 CNVs have been suggested to associate with spermatogenesis (Shen et al. 
2013). Further studies of TSPY1 or other Y-originating fragments in MA patients have not 
been reported and no further associations of the gene with MD regression has been shown 
to date. 
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Taken together, we investigated if fragments of the Y chromosomal DNA are present in MA 
patient samples indicating a role for Y chromosomal genes in the etiology of the disorder. 
Our results clearly show that the studied Y chromosomal regions are not involved in MA, at 
least not in this Finnish patient cohort. Our results also show the importance of confirming 
specificity of nested PCR products by sequencing and not by gel electrophoresis alone, as in 
the study by Plevraki and coworkers (Plevraki et al. 2004). 
 
5.2?DNA?methylation?studies?of?H19?in?Müllerian?aplasia?(Study?II)?
 
Epigenetic studies, such as DNA methylation measurements, are of importance when 
studying imprinted genes involved in genetic disorders. H19 is an example of such a gene, 
which has been suggested to associate with MA. Namely, in a  study by  Bliek and 
coworkers, hypomethylation (low methylation compared to the normal state) of the H19 
imprinting control region ICR1 was shown to associate with Silver Russel syndrome (SRS) 
patients with genital and skeletal malformations (Bliek et al. 2006). Hypomethylation of H19 
(Gicquel et al. 2005, Eggermann et  al. 2006)  and  maternal  uniparental  disomy  of  
chromosome 7 (matUPD7) are previously known important causes of SRS (Moore et  al. 
1999), but also genital malformations were reported in these patients. Furthermore, Bruce 
et al. described two Finnish SRS patients with extreme H19 ICR1 hypomethylation (Bruce et 
al. 2009), and interestingly, both patients also had MA. These findings inspired us to study if 
1) hypomethylation of the H19 ICR1 site 25 is associated with the MA phenotype and if 2) 
altered methylation of the H19 gene per se is associated with MA. 
 
Eighty Finnish MA patients were studied for DNA methylation status at the H19 ICR1-HpaII 
site 25 by qPCR, according to Bruce et al. (Bruce et al. 2008). In practice, this was performed 
by comparing the relative amount of qPCR products amplified from DNA samples digested 
with the methylation-sensitive HpaII restriction enzyme (unable to cut methylated cytosine) 
versus undigested samples. The methylation level of the H19 ICR1 site 25 did not differ 
significantly between MA patients and controls with mean methylation 47.5% (SD, 7.0%) for 
patients and 50.2% (SD, 10.8%) for controls (Table 6). The results indicate that 
hypomethylation of the investigated site is not associated with the MA phenotype. 
 
Table 6. Statistical comparison of methylation values (%) from the qPCR studies of the H19 
ICR1. 
Sample Number (N) Mean (std) Median p value 
All MA patients 80 47.5 (7.0) 46.1 0.215a 
Controls 20 50.2 (10.8) 49.6  
ap value derived from Mann-Whitney U test. 
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H19 belongs to one of the most studied complexes of imprinted genes, the IGF2-H19 locus 
on 11p15.5. Insulin-like growth factor 2 (IGF2) and H19 are neighboring genes regulated by 
the  same  ICR1  complex  (also  called  the  H19 DMR),  which  is  a  paternally  methylated  
germline DMR (Weksberg et al. 2002). IGF2 is expressed from the paternally derived allele, 
whereas H19 is expressed from the maternally derived allele. The IGF2-H19 locus is 
associated with two clinically opposite disorders, SRS and Beckwith-Wiedemann syndrome 
(BWS), displaying almost mirror phenotypes. SRS patients suffer from intrauterine and 
postnatal growth retardation defects (Eggermann 2010), whereas BWS patients suffer from 
fetal and postnatal overgrowth (Choufani et  al. 2010).  BWS  can  be  caused  by  
hypermethylation of ICR1 on the maternal allele promoting IGF2 expression from both 
alleles instead of only one. On the other hand, hypomethylation of ICR1 on the paternal 
allele promotes expression of H19 from both alleles, resulting in downregulation of IGF2 and 
a SRS phenotype (Eggermann 2010). CTCF (or CCCTC-binding factor) is a major mediator of 
imprinted gene regulation, and hypomethylation of the HpaII site  25  situated  nearby  the  
CTCF site 3 within the H19 ICR1 was reported to associate with genital malformations in SRS 
patients (Gicquel et al. 2005, Bruce et al. 2009) 
 
To further investigate the general methylation level of H19, 38 MA patients and six controls, 
of which 35 patients and all controls were included in the qPCR study, were screened using 
HumanMethylation27 methylation arrays (HM27; Illumina). HM27 is a genome-wide 
methylation bead chip covering >27000 CpG sites, of which 16 sites are situated in H19. A 
total of 3/16 CpG sites investigated showed statistically significant methylation differences 
(p-value <0.05) between patients and controls (Table 7). The methylation differences 
between patients and controls were, however, small in all studied sites. Therefore, after 
FDR correction for multiple testing, the methylation levels were not significant and the 
effect of this on a transcriptional level is uncertain. The observed methylation level was 61-
98% in both patients and controls in all studied sites within H19 (CpG sites 1-14), whereas 
the  CpG  sites  15  and  16  situated  5´upstream  of  the  transcribed  region  had  a  lower  
methylation level (37-75%). 
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Table 7. Location of studied CpG sites H19 and their methylation data based on 
HumanMethylation27  microarray (Illumina). 
 
 Probe name Location CpG MA patients (n=38) Controls (n=6) 
 
 within H19a island mean (std) pb qc mean (std) 
1 cg11492040 exon 5 1? 0.96 (0.01) 0.785 0.897 0.96 (0.01) 
2 cg06197492 exon 5 1? 0.84 (0.04) 0.150 0.400 0.86 (0.03) 
3 cg10602543 exon 5 1? 0.82 (0.03) 0.270 0.540 0.83 (0.03) 
4 cg23977670 exon 5 1? 0.89 (0.02) 0.555 0.807 0.90 (0.01) 
5 cg11716026 exon 5 1? 0.83 (0.04) 0.416 0.666 0.79 (0.10) 
6 cg22172494 exon 3 2? 0.81 (0.05) 0.012 0.107 0.86 (0.04) 
7 cg26808784 intron 2-3 2? 0.91 (0.02) 0.971 0.971 0.91 (0.01) 
8 cg25852472 intron 1-2 2? 0.81 (0.03) 0.014 0.107 0.84 (0.04) 
9 cg15269875 exon 1 2? 0.93 (0.01) 0.111 0.355 0.93 (0.01) 
10 cg21167159 exon 1 2? 0.89 (0.03) 0.908 0.969 0.89 (0.03) 
11 cg13145013 exon 1 2? 0.96 (0.01) 0.782 0.897 0.96 (0.01) 
12 cg15317267 exon 1 2? 0.92 (0.01) 0.183 0.418 0.93 (0.01) 
13 cg04715462 exon 1 2? 0.98 (0.01) 0.020 0.107 0.98 (0.00) 
14 cg07342901 exon 1 d 0.93 (0.02) 0.606 0.808 0.92 (0.03) 
15 cg17769238 5´upstream 3? 0.59 (0.05) 0.369 0.656 0.57 (0.03) 
16 cg02657360 5´upstream 4? 0.48 (0.05) 0.063 0.252 0.44 (0.04) 
a according to Ensembl GRCh37(hg19). 
bp value derived from independent samples t-test performed between MA patients and controls. 
c p value after false discovery rate (FDR) correction. 
d not located on a known CpG island. 
 
 
H19 is a non-coding RNA abundantly expressed in mammalian development with largely 
unknown biological function. H19 belongs to a network of imprinted genes associated with 
embryonic growth (Gabory et al. 2009, Gabory et al. 2010) and it is therefore possible that 
the observed methylation reduction has an impact on expression of other genes acting 
within the same network and with a function in MD development.  It has also been shown 
that H19 acts as a tumour suppressor (Yoshimizu et al. 2008), and that the first exon of the 
gene encodes a microRNA that regulates placental growth, which might be relevant for 
normal growth of the fetus (Keniry et  al. 2012). The three CpG sites showing significant 
differences in p-values between patients and controls in the HM27 study are all situated 
within  the  same  CpG  island  and  one  of  the  sites  is  located  in  exon  1  (Figure  6).  One  can  
therefore speculate that reduced methylation levels within the H19 gene itself could 
contribute to the MA phenotype. The results should, however, be validated in a larger 
patient cohort including more controls in order to obtain robust statistical significance for 
the findings. 
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Figure 6. Schematic view of the H19 genomic structure and locations of the HumanMethylation27 
Bead Array CpG sites with corresponding CpG islands. Three  CpG  sites  (6,  8  and  13)  show  
statistically significant differences in methylation levels between MRKH patients and controls. The 
H19 ICR1 studied by qRT-PCR is indicated by an arrow. IGF2 = Insulin-like growth factor 2 gene. 
 
 
In summary, hypomethylation of H19 ICR1 is not a cause of MA in the investigated sample 
set including 80 Finnish patients with MA. The previously reported association between SRS 
patients with reproductive duct malformations and H19 ICR1 hypomethylation were 
observed  only  in  two  patients  per  study  (Bliek et  al. 2006, Bruce et al. 2009), and could 
therefore be correlated to a phenotype other than MA, or be coincidental. Growth 
restriction, a main feature of SRS, is also not included in the MA phenotype spectrum, and 
none of the MA patients have been reported to have other features suggestive of SRS. 
 
 Our results on the patients´ methylation state of several CpGs within H19 compared  to  
controls were not statistically significant after adjusting for FDR but are, however, indicative 
and interesting for further studies in larger patient cohorts or in other populations. In 
particular, studies involving other CTCF-sites within H19 ICR1 and their methylation levels, 
or other imprinted genes, could be relevant to the disorder. This, in addition to previous 
findings of monozygotic twins discordant for MA (Lischke et al. 1973, Steinkampf et al. 2003, 
Duru et al. 2009), as well as healthy female children born to MA patients (Petrozza et al. 
1997), encourage further epigenetic studies in MA for finding the underlying cause for at 
least some of the patients. 
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5.3?SHOX? copy?number?variations? in?patients?with?Müllerian?aplasia?
(Study?III)?
 
In this study our aim was to evaluate the role of SHOX CNVs  in  the  Finnish  cohort  of  MA  
patients. This was based on a previous report by Gervasini et al. suggesting that partial 
duplications of the SHOX gene are associated with MA (Gervasini et al. 2010). 
 
DNA samples from 111 Finnish MA patients and 115 healthy controls were studied for CNVs 
in SHOX using the commercial MLPA assay (SALSA MLPA kit P018-E1 SHOX, MRC-Holland, 
Amsterdam, the Netherlands). SHOX is alternatively spliced into two main transcripts, 
SHOXa and SHOXb,  with  a  non-coding  first  exon  followed  by  six  protein-coding  exons,  of  
which  the  last  exon  differs  between  the  two  transcripts  (6a  or  6b)(Leka et al. 2006). We 
used an MLPA assay that included 43 probes covering the first six exons of SHOX, its 
promoter region, a unique intron sequence before exon 6b and a region downstream of the 
gene.  The SHOX probes for exons 1-3 and 5-6a were the same as in the MLPA assay used by 
Gervasini and coworkers (PO18-B), whereas the probes for exon 4 and 6b had been replaced 
by the manufacturer in the assay used in our study (P018-E1). All aberrant amplification 
results were confirmed in a second independent MLPA analysis. 
 
All investigated MA samples within our study had normal amplification of SHOX, in other 
words two copies of the gene were detected in all patient and control samples. In five MA 
patient samples and seven control samples, CNVs downstream of SHOX were found (Figure 
7; Table 8). 
 
 
 
 
 
Figure 7. Comparison of CNV results within and downstream of SHOX detected in MA patients 
(P)and controls (C) using MLPA. CNVs reported by Sandbacka et al. (2011) are illustrated above the 
schematic view of the studied genomic region, whereas CNVs reported by Gervasini et al. (2010) are 
illustrated below. CNVs spanning more than two probes are indicated by lines, whereas CNVs 
detected by one probe are indicated with a letter. Gains are in green and losses in purple. Samples 
containing two CNVs are indicated by *. Tel = telomere. 
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All observed CNVs downstream of SHOX were previously reported in the Database of 
Genomic Variants (DGV; http://projects.tcag.ca/variation/) and are therefore most likely 
common polymorphisms. Furthermore, the 12 samples with CNVs detected downstream of 
SHOX contained one CNV each, except one patient sample and one control sample 
containing two aberrations. Another control sample had a larger duplication consisting of 11 
probes (Table 8). 
 
Table 8. CNVs (gains and losses) downstream of SHOX detected in Finnish MA patients and 
controls using MLPA assays (SALSA MLPA kit P018-E1 SHOX, MRC-Holland). 
 
Region/gene Aberration MLPA probe Cases Controls Reference 
Xp22.32-PAR1 Gain 09335-L15508a 1* 1* DGVb, Gervasini et al. 
2010 
Xp22.32-PAR1 Loss 09335-L15508 1 1 DGV 
Xp22.32-PAR1 Gain 14697-L16348 1* 1* DGV 
Xp22.32-PAR1 Loss 14697-L16348  1 DGV 
Xp22.32-PAR1 
to CRLF2 
Gain 13296-L15336  -
13911-L16505 
 1 all 11 probes reported in 
DGV 
CSF2RA Gain 10251-L15502  2 DGV 
IL3RA Gain 13597-L15055 1  DGV 
ASMT Gain 01153-L00712c 2 1 DGV, Gervasini et al. 2010 
a the probe sequence partly overlaps with MLPA probe 5650-L5104 from version PO18-B SHOX used 
by Gervasini et al. 2010. 
b DGV (Database of Genomic Variants, http://projects.tcag.ca/variation) 
*one patient and one control sample contain two aberrations each 
c the probe corresponds to MLPA probe 1153-L0712 from version PO18-B SHOX used by Gervasini et 
al. 2010. 
 
 
The SHOX gene is situated in the pseudoautosomal region of the X (Xp22) and Y (Yp11.3) 
chromosomes, and is therefore normally present in two copies in both sexes. Mutations and 
CNVs (duplications and deletions) in SHOX have previously been reported to contribute to 
several short stature disorders, such as idiopathic short stature (ISS, OMIM 300582), Turner 
syndrome (Ellison et  al. 1997, Rao et al. 1997), dyschondrosteosis (Leri-Weill syndrome, 
LWD, OMIM 127300) and Langer mesomelic dysplasia (OMIM 249700)(Belin et al. 1998, 
Shears et al. 1998, Benito-Sanz et al. 2011). Previous reports of patients with duplications in 
SHOX are rare and include a total of only five patients, of whom none were reported with 
MA (Grigelioniene et al. 2001, Ogata et  al. 2001, Roos et  al. 2009, Thomas et al. 2009, 
D'haene et  al. 2010, Benito-Sanz et al. 2011). For one of the patients the duplication was 
also found in her healthy sister, thereby questioning the functional effect of the CNV 
(Grigelioniene et al. 2001). 
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In the study by Gervasini et al. (2010) including 30 MA patients, the familial MA patients 
(3/3) and 7% of the sporadic patients (2/27) were reported to have partial duplications of 
SHOX corresponding to two or more exons of the gene and ranging in size from 7 to >300 kb 
(Figure 7). The entire SHOX gene was not duplicated in any of the samples (Gervasini et al. 
2010). In the familial cases, the research group showed that both sisters with MA shared the 
same duplication as well as the same haplotype for the aberrant region as their healthy 
father,  which  was  lacking  from  the  two  healthy  sisters  and  their  mother.  This  would  
correspond to a sex-limited dominant inheritance transmitted through a healthy father, 
suggested already in 1978 by Shokeir (Shokeir 1978). 
 
In our study including a more than three times larger patient cohort (101 Finnish MA 
patients), of whom two were familial (sisters), the expected number of patients with SHOX 
aberrations if the frequencies were the same would be nine including both sisters and seven 
sporadic patients. However, none of the studied patients in our study were found to carry 
intragenic CNVs in SHOX. Our results do not confirm their findings, but on the contrary 
suggest that SHOX CNVs are not the cause of MA, at least not in the Finnish patient cohort, 
and  are  unlikely  to  be  a  major  cause  of  MA  worldwide.  We  chose  to  use  the  same  
experiment for detecting deletions and duplications in SHOX, the MLPA method, as the 
Gervasini group, in order to achieve comparable results. The intragenic SHOX probes for 
exon 4 and 6b had been replaced in the MLPA assay when compared to that in the Italian 
report, but since the intragenic SHOX duplications reported by Gervasini and coworkers all 
spanned more than one probe, corresponding CNVs would also have been detected in the 
Finnish cohort if they existed. However, in a complex trait population differences may exist 
and underlie the discordant results. Additionally, the positive findings by the Italian group 
might be coincidental without actual association to the MA phenotype. 
 
5.4? TBX6?? LHX1? and? copy? number? variations? in? Müllerian? aplasia?
(Study?IV)?
 
The focus of this study was to find novel genes and CNVs associated with the development 
of MA. At the start of the study, mutations in only two genes, WNT4 and LHX1, were known 
to cause MA and the number of patients reported with mutations  ( a total of six) was small 
(Biason-Lauber et al. 2004, Biason-Lauber et al. 2007, Philibert et  al. 2008, Philibert et al. 
2011, Ledig et al. 2011, Ledig et al. 2012). 
 
Fifty MA patients, all diagnosed by laparoscopy, were investigated with aCGH (180 K 
platform, Oxford Gene Technology, Yarnton, Oxford, UK) revealing rare CNVs in 8/50 (16%) 
(Table  9).  Seven  of  the  CNVs  were  deletions  found  in  one  patient  each  and  two  were  
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duplications,  found  in  the  same  patient.  Five  of  the  deletions  (5p14.3,  9q21.13,  11q13.4,  
15q26.1 and 16p13.3) and both duplications (19q13.11 and 19q13.12) were novel and not 
reported in DGV, whereas two deletions had been previously reported in association with 
MA. These were the 17q12 (Cheroki et al. 2008, Bernardini et al. 2009, Ledig et al. 2011, Nik-
Zainal et al. 2011) and 16p11.2 deletions (Nik-Zainal et al. 2011) sized 1.7 Mb and 0.53 Mb, 
respectively. 
 
Table 9. CNVs in a set of MA patients detected using aCGH. 
 
Locus Patient 
ID 
Size CNV Genes within CNV Confirmation 
method 
5p14.3 28 1.6 Mb Del CDH18 SNP array, qPCR 
9q21.13 3 95 Kb Del TMEM2 SNP array 
11q13.4 2 54 Kb Del CHCHD8, PAAF1 SNP array, qPCR 
15q26.1 4 96 Kb Del ZNF774, IQGAP1 SNP array, qPCR 
16p11.2 69  0.53 
Mb 
Del SPN, QPRT, C16orf54, MAZ, 
PRRT2, C16orf53, MVP, CDIPT, 
LOC440356, SEZ6L2, ASPHD1, 
KCTD13, TMEM219, TAOK2, 
HIRIP3, INO80E, DOC2A, C16orf92, 
FAM57B, ALDOA, PPP4C, TBX6, 
YPEL3, GDPD3, MAPK3, 
LOC100271831 
SNP array 
16p13.3 42 143 Kb Del A2BP1 SNP array, qPCR 
17q12 24 1.7 Mb Del TBC1D3C, CCL3L1, CCL3L3, 
CCL4L2, CCL4L1, TBC1D3H, 
TBC1D3C, TBC1D3G, ZNHIT3, 
MYO19, PIGW, GGNBP2, DHRS11, 
MRM1, LHX1, AATF, ACACA, 
C17orf78, TADA2L, DUSP14, 
AP1GBP1, DDX52, HNF1B, 
LOC284100 
SNP array 
19q13.11a 49 194 Kb Dupl RHPN2, GPATCH1, WDR88, LRP3, 
SLC7A10 
SNP array, qPCR 
19q13.12a 49 0.6 Mb Dupl LSR, USF2, HAMP, MAG, CD22, 
FFAR1, FFAR3, FFAR2, KRTDAP, 
DMKN, SBSN, GAPDHS, TMEM147, 
ATP4A,  HAUS5,  RBM42,  ETV2,  
COX6B1, UPK1A, ZBTB32, MLL4, 
TMEM149, U2AF1L4, PSENEN, 
LIN37, HSPB6, C19orf55, SNX26, 
PRODH2 
SNP array, qPCR 
a likely to include non-duplicated regions, possibly due to other chromosomal rearrangements e.g. 
inversions within the region or non-functional aCGH probes. 
CNV = copy number variations, Del = deletion, Dupl = duplication. 
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The  17q12  region  embraces  24  genes  including  LHX1, for which mutations in MA were 
reported (Ledig et al. 2011, Ledig et al. 2012), and HNF1B, which has been studied in MA but 
thus far no mutations have been found (Bernardini et al. 2009, Ledig et al. 2011). 17q12 
deletions of the same size have previously been associated with renal malformations and 
cysts, growth restriction, speech problems (Mefford et al. 2007, Nagamani et al. 2010) and 
autism (Loirat et al. 2010), whereas duplications have been associated with cognitive 
impairment, epilepsy, and renal and urinary malformations (Mefford et al. 2007, Nagamani 
et al. 2010). Deletions in 16p11.2 have previously been documented in association with 
autism (Kumar et al. 2008, Weiss et al. 2008), developmental delay (Rosenfeld et al. 2010) 
and obesity (Walters et al. 2010), whereas duplications in 16p11.2 have been reported in 
association with autism (Weiss et  al. 2008), developmental delay (Rosenfeld et al. 2010), 
and schizophrenia (McCarthy et al. 2009). 16p11.2 includes at least 26 genes, of which TBX6 
is the only gene with known function in embryonic development (White et  al. 2003). We 
therefore continued to investigate TBX6 and LHX1 as candidate genes for MA. 
 
MLPA and Sanger sequencing of TBX6 was performed in the patient cohort that at this point 
was extended to embrace 112 MA patients (110 Finnish and two foreign). MLPA revealed 
monoallelic deletion of TBX6 in 5/112 patients, of which one was the patient with the 0.53 
Mb deletion on 16p11.2 originally detected by aCGH. Validation studies by SNP genotyping 
(HumanOmni2.5-8 BeadChip v1.0, Illumina, San Diego, CA, USA) confirmed that also the 
other four patients had the same 16p11.2 deletion including TBX6. 
 
Sanger sequencing of TBX6 revealed a novel splice site variant (c.622-2A>T; g.30100162T>A) 
in 2/112 MA patients (1.8%) (Table 10). This heterozygous A>C change is located in the 
highly  conserved  splice  acceptor  site  (AG)  of  exon  5.  The  variant  was  not  observed  when  
sequencing 200 healthy female control samples, not reported in dbSNP, the 1000 Genomes 
database, in 1532 alleles of Finnish ancestry (A-P Sarin and A. Palotie, personal 
communication, 2013) or in the Exome Variant Server (EVS), where TBX6 sequence data is 
available for >12000 alleles of African American and European American ancestry. The splice 
site variant is located within the evolutionally highly conserved DNA-binding T-box element 
of the gene (Figure 8). In silico prediction programs indicated that the mutation would 
disrupt the correct splicing of the transcript. RT-PCR revealed at least three different 
transcripts present in both patients and healthy controls. 
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Figure 8.  A schematic  view of  TBX6 with  arrows indicating the c.622-2A>T mutation,  and the rare  
missense variants in exon 4 (g.30100401C>T; p.Gly162Ser; rs56098093) and exon 6 (g.30099890C>T; 
p.Arg272Gln; rs201231713) of the gene (Sandbacka et al. 2013). 
 
 
 
By sequencing we also found six TBX6 variants, all previously reported in dbSNP (Table 10). 
Interestingly, two of the variants were rare (exon 4 rs56098093 and 6 rs201231713) and 
statistically significantly more common in patients than in controls. The MAF for rs56098093 
was 8.0% for patients compared to 2.0% for controls and for rs201231713 5.8% for patients 
compared to 2.0% for controls. The differences were statistically significant (P-value 0.0021 
(rs56098093) and 0.0002 (rs201231713), also after correction for multiple testing according 
to Bonferroni (P-value/2 < 0.05), indicating that the variants might increase the risk for the 
disorder.  Noteworthy is that two patients were homozygous for both of the variants, 
whereas none of the 200 sequenced controls were homozygous for either of them. 
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Table 10. A summary of TBX6 and LHX1 variants found by Sanger sequencing 112 MA patients (110 
Finnish and 2 foreign). The novel and rare variants are shown in bold. 
 
avariations presented according to genomic reference sequence for TBX6: (g.) NC_000016.9, coding 
DNA reference sequence (c.) NM_004608.3 and protein reference sequence (p.) NP_004599.2, 
(Genome Build 37.3, dbSNP), and for LHX1: (g.) NC_000017.10, (c.) NM_005568.3 and (p.) 
NP_005559.2 (Genome Build 37.3, dbSNP). 
brs numbers for previously known SNPs according to dbSNP or Exome Variant Server (EVS). 
c1/12783 alleles reported in EVS. 
dnumber of genotypes reported as: reference allele/reference allele ; reference allele/alternative 
allele ; alternative allele/alternative allele. 
 
Mouse knockout studies have shown Tbx6 to be important for somite segmentation in the 
paraxial mesoderm during embryogenesis (Chapman et al. 1998). A link between the Wnt 
signaling pathway and Tbx6 is suggested through interactions with Notch-ligand delta-like 1 
(Dll1) (White et al. 2003). Moreover, a spontaneous mouse model for Tbx6, the homozygous 
Tbx6rv (rib-vertebrae) has in addition to segmentation problems skeletal and urogenital 
Gene and 
location within 
gene 
Varianta 
Predicted 
change 
rs numberb Genotype of 
patientsd 
N=112 
Genotype of 
controlsd 
N=200 (TBX6) 
N=180 (LHX1) 
TBX6, intron 2 g.30102391G>A 
c.118+6C>T 
rs112565029 CC: 107 (95.5%) 
CT: 5 (4.5%) 
TT: 0 (0%) 
CC: 187 (93.5%) 
CT: 13 (6.5%) 
TT: 0 (0%) 
TBX6, exon 4 g.30100402G>A 
p.Ser161= 
rs147485102 CC: 111 (99.1%) 
CT: 1 (0.9%) 
TT: 0 (0%) 
CC: 198 (99%) 
CT: 2 (1%) 
TT: 0 (0%) 
TBX6, exon 4 g.30100401C>T 
p.Gly162Ser 
rs56098093 GG: 97 (86.6%) 
GA: 12 (10.7%) 
AA: 3 (2.7%) 
GG: 192 (96%) 
GA: 8 (4%) 
AA: 0 (0%) 
TBX6, intron 4 g.30100162T>A 
c.622-2A>T 
- AA: 11 (98.2%) 
AT: 2 (1.8%) 
TT: 0 (0%) 
AA: 200 (100%) 
AT: 0 (0%) 
TT: 0 (0%) 
TBX6, exon 6 g.30099890C>T 
p.Arg272Gln 
rs201231713 GG: 101 (90.2%) 
GA: 9 (8.0%) 
AA: 2 (1.8 %) 
GG: 198 (99%) 
GA: 2 (1%) 
AA: 0 (0 %) 
TBX6, intron 7 g.30098022G>A 
c.914-6C>T 
rs200310768 CC: 109 (97.3%) 
CT: 3 (2.7%) 
TT: 0 (0%) 
CC: 194 (97%) 
CT: 6 (3%) 
TT: 0 (0%) 
TBX6, exon 9 g.30097630C>T 
p.Pro409= 
rs2289292 GG: 32 (28.6%) 
GA: 55 (49.1%) 
AA: 25 (22.3%) 
GG: 67 (33.5%) 
GA: 95 (47.5%) 
AA: 38 (19%) 
LHX1, exon 1 g.35295505G>C 
p.Cys4Ser 
- GG: 111 (99.1%) 
GC: 1 (0.9%) 
CC: 0 (0%) 
GG: 180 (100%) 
GC: 0 (0%) 
CC: 0 (0%) 
LHX1, exon 5 
 
g.35300142C>A 
p.Pro312His 
- CC: 109 (97.3%) 
CA: 3 (2.7%) 
AA: 0 (0%) 
CC: 180 (100%) 
CA: 0 (0%) 
AA: 0 (0%) 
LHX1, exon 5 g.35300202C>G 
p.Pro332Arg 
TMP_ESP_17
_35300202c 
CC: 111 (99.1%) 
CG: 1 (0.9%) 
GG: 0 (0%) 
CC: 180 (100%) 
CG: 0 (0%) 
GG: 0 (0%) 
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malformations (Theiler et al. 1985, Watabe-Rudolph et  al. 2002),  thereby  resembling  the  
MA phenotype.  In humans, a Macedonian family has been reported with a missense 
mutation in the last codon of the TBX6 transcript resulting in segmentation defects of the 
vertebrae (Sparrow et al. 2013). TBX6 has also been associated with congenital scoliosis in 
the Chinese Han population (Fei et al. 2010).  
 
Sequencing of LHX1 in the patient cohort revealed three novel missense variants in 5/112 
(4.4%) MA patients (Table 10; Figure 9). None of the variants are reported in dbSNP, and 
only the p.Pro332Arg was previously reported in EVS, in 1/12783 alleles. In silico predictions 
indicated the exon 1 variant as deleterious, while the data for the other two were 
discrepant. The patient with the exon 1 mutation was from the Middle East and the four 
other patients Finnish. 
 
Figure 9:  A schematic  view of  LHX1 with the novel DNA variants (resulting in Cys4Ser, Pro312His 
and Pro332Arg) shown at corresponding locations at nucleotide and protein levels. The two 
previously known LHX1 variants (Arg9LysfsX25 and Arg264Gly; Ledig et al. 2011 and 2012) are 
indicated by *. Aa corresponds to amino acid. 
 
Taken together, we were able to identify TBX6 as a new gene associated with the 
development of MA. Our findings strengthening this statement included a deletion of 
16p11.2, embracing TBX6,  found  in  5/112  MA  patients,  a  novel  TBX6 splice site mutation 
found in 2/112 patients, and two rare TBX6 variants in exon 4 and exon 6, both significantly 
more common in patients (8% and 5%, respectively) than in controls (2%). We also found 
three novel LHX1 variants in 5/112 patients, strengthening the relevance of the gene in MA 
development. Additionally, we found seven rare CNVs not previously associated with MA, 
denoting the genes located within the aberrant regions as important candidate genes in 
further MA studies. Altogether, we identified either CNVs or TBX6 or LHX1 variants in 
30/112 (26.8%) MA patients. CNVs were found in 12/112 (10.7%), patients, novel TBX6 or 
LHX1 variants in 7/112 (6.3%) patients, and rare TBX6 variants in 15/112 (13.4%) patients.  
Importantly, four patients (4/112, 3.6%) were carrying variants in both TBX6 and LHX1 or a 
TBX6 variant in combination with a CNV, supporting the multifactorial etiology of MA. 
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6. General? discussion,? concluding? remarks? and? future?
prospects?
 
The aim of this study was to investigate the genetic background and identify novel genetic 
causes of MA. This syndrome is rare, however affecting at least 1 in 5000 female births. In 
the Finnish population with a size of 5.4 million and approximately 60 000 births per year, 
the  estimated  number  of  new  cases  is  at  least  six  (0.0002  x  30  000)  per  year.  With  an  
average life expectancy of 83 years for women in Finland, this means that at least 500 
females have MA in our country today. The MA frequency is estimated to be approximately 
the same world-wide. 
 
MA is regarded as one of the difficult disorders of female health. It is featured by congenital 
loss of functional uterus and vagina and is commonly diagnosed at the age of 14-16 due to 
primary amenorrhea (absent menses). The vagina is undeveloped and exists only as a small 
pouch and therefore treatment is needed for commencing a normal sex life.  The lack of 
uterus leads to infertility, even if MA patients mostly have normal oocyte-producing ovaries. 
Legal and ethical acceptance for surrogacy could provide MA patients with biological 
children. Uterine transplantation could offer another possibility for MA women to become 
pregnant in the future, but is still in an initial phase and necessitates much research and 
ethical discussion in order to become a real-life alternative. Therefore, adoption is presently 
the only possibility for parenthood among MA women in Finland. The diagnosis of MA often 
leads to psychosocial problems. Many patients will not share the diagnosis even with their 
family and closest friends due to the sensitivity of the syndrome.  
 
Previously,  only  mutations  in  two  genes,  namely  WNT4 and LHX1,  were  linked  to  MA  and  
only in a handful of patients world-wide. In addition to these mutations, CNVs were 
suggested as causative for the disorder, but again in a small number of patients. Therefore, 
the cause of the disorder is still unknown for the majority of patients and the genetics of MA 
is considered multifactorial with mutations in several genes or genomic rearrangements 
with incomplete penetrance and variable expressivity playing part in its etiology. However, 
for a subgroup of patients or for specific populations, a monogenic form of MA might exist. 
 
 This  study  investigated  the  role  of  Y  chromosomal  fragments,  CNVs  as  well  as  DNA  
methylation  defects  to  underlie  MA  in  a  large  Finnish  cohort  of  MA  patients,  the  second  
largest MA cohort world-wide published to date. We have also performed collaborative 
studies with researchers both in Sweden and Brazil in order to improve our methodological 
knowledge and to test our study hypothesis. The results show that Y chromosomal factors 
and SHOX CNVs do not have a role in the etiology of the disorder in Finnish patients. 
However, as MA is a complex multifactorial disorder, population-differences may occur. Our 
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studies on the DNA methylation status of the imprinted gene H19 and its control region ICR1 
indicate  that  DNA  methylation  and  epigenetic  factors  in  general  can  have  a  role  for  a  
subgroup of MA patients. However, further studies in this field are needed. 
 
This study confirmed the previous findings that CNVs in 16p11.2 and 17q12 are associated 
with MA. Furthermore, we identified TBX6 as a new gene with mutations in MA patients as 
we  found  two  Finnish  patients  to  carry  splice  mutations.  In  addition  to  the  mutation,  we  
also found two rare variants to be more frequent in patients than in healthy controls, and 
we therefore suggest that they are important in MA etiology. We were also able to reveal 
three novel mutations in five patients in the LHX1 gene, recently found to be linked to MA, 
as  well  as  rare  CNVs,  a  basis  for  future  candidate  gene  studies.  To  summarize,  within  the  
frameworks of this study, 6% (7/112) patients were found with mutations most likely 
causative of the disorder and 24% (27/112) with suggestive causes (rare variants and CNVs) 
adding up to 30% (34/112) of the patients with a genetic cause that could underlie MA. We 
were  also  able  to  show  that  four  MA  patients  (3.4%)  carried  variations  in  both  TBX6 and 
LHX1 or in TBX6 in combination with CNVs exemplifying the complex genetics of MA. 
 
Limitations  in  this  study  include  the  problem  with  investigating  a  tissue  that  is  missing  -  
expression studies based on tissue samples are not possible. Additionally, the time point of 
MD development (or regression), which occurs in the early weeks of human embryonic 
development, restrict the research possibilities. Functional studies based on our TBX6 and 
LHX1 mutation findings to prove their role in the development of MA would be important to 
perform. The private nature of MA also challenges the possibilities of collecting samples 
from families, which would be valuable for haplotype and inheritance screening. Genome-
wide association studies in order to reveal new candidate loci have been performed in 
several complex disorders such as diabetes and cancer. However, these studies require 
thousands  or  tens  of  thousands  of  samples  in  order  to  give  reliable  results,  which  is  not  
possible in rare and sensitive disorders like MA. Increased knowledge of MA and other 
reproductive disorders in the general population would be helpful for both the patients and 
their families as well as for the research within the field.  
 
In this study several negative findings were encountered. Our study designs and methods of 
choice were selected based on high efficiency, sensitivity and reliability and therefore we 
believe that these are true findings. Our negative findings can be due to previous studies 
being performed in small patient cohorts with different population backgrounds or that the 
original findings are not relevant for MA. Establishment of an international MA consortium 
with collaboration and data sharing between research groups world-wide could be a good 
platform for future discoveries in the field. 
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Future goals within the MA project are to further explore the candidate genes within the 
newly described CNVs and also add them to the previously associated CNVs in order to find 
gene families or pathways that might be involved in the development of MA. Further, 
combining genome-wide SNP genotype with DNA methylation data could give clues to new 
genes or genetic regions with shared haplotypes in conjunction with aberrant DNA 
methylation patterns for future candidate gene studies. Mutation screening by exome 
sequencing is presently being pursued in the project. Samples from healthy family members 
would be valuable to gather and include, in order to exclude variants without biological 
relevance to the disorder. Finding out more about the underlying causes of MA, could in the 
future also enable genetic counseling for the patients. 
 
In this study, we are able to give an answer for the probable genetic cause of MA to almost 
one third of the Finnish MA patients, which is a significant number compared to what was 
previously known. Every new discovery is a step forward in MA research and even if there is 
no treatment today for the infertility caused by MA, gradually deciphering the genetic 
causes of MA might help the patients and families in their everyday life.  
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